Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.
Breaks in bones.
Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Fractures occurring as a result of disease of a bone or from some undiscoverable cause, and not due to trauma. (Dorland, 27th ed)
A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
Tumors or cancer of the human BREAST.
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
The constricted portion of the thigh bone between the femur head and the trochanters.
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
Broken bones in the vertebral column.
Bone loss due to osteoclastic activity.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
Therapeutic use of hormones to alleviate the effects of hormone deficiency.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
The surgical removal of one or both ovaries.
Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
Calcium compounds used as food supplements or in food to supply the body with calcium. Dietary calcium is needed during growth for bone development and for maintenance of skeletal integrity later in life to prevent osteoporosis.
An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.
A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Sex hormone-binding protein has the same amino acid sequence as ANDROGEN-BINDING PROTEIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.
3-Phenylchromones. Isomeric form of FLAVONOIDS in which the benzene group is attached to the 3 position of the benzopyran ring instead of the 2 position.
A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Physiologic period, characterized by endocrine, somatic, and psychic changes with the termination of ovarian function in the female. It may also accompany the normal diminution of sexual activity in the male.
Steroid hormones produced by the GONADS. They stimulate reproductive organs, germ cell maturation, and the secondary sex characteristics in the males and the females. The major sex steroid hormones include ESTRADIOL; PROGESTERONE; and TESTOSTERONE.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Vitamin K-dependent calcium-binding protein synthesized by OSTEOBLASTS and found primarily in BONES. Serum osteocalcin measurements provide a noninvasive specific marker of bone metabolism. The protein contains three residues of the amino acid gamma-carboxyglutamic acid (Gla), which, in the presence of CALCIUM, promotes binding to HYDROXYAPATITE and subsequent accumulation in BONE MATRIX.
The largest of the TARSAL BONES which is situated at the lower and back part of the FOOT, forming the HEEL.
Pregnenes with one double bond or more than three double bonds which have undergone ring contractions or are lacking carbon-18 or carbon-19..
The spinal or vertebral column.
The longest and largest bone of the skeleton, it is situated between the hip and the knee.
The outer shorter of the two bones of the FOREARM, lying parallel to the ULNA and partially revolving around it.
(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator.
The transitional period before and after MENOPAUSE. Perimenopausal symptoms are associated with irregular MENSTRUAL CYCLE and widely fluctuated hormone levels. They may appear 6 years before menopause and subside 2 to 5 years after menopause.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.
A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)
The concept covering the physical and mental conditions of women.
The projecting part on each side of the body, formed by the side of the pelvis and the top portion of the femur.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
PLANT EXTRACTS and compounds, primarily ISOFLAVONES, that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)
The most common form of fibrillar collagen. It is a major constituent of bone (BONE AND BONES) and SKIN and consists of a heterotrimer of two alpha1(I) and one alpha2(I) chains.
Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone.
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.
Proteins which are present in or isolated from SOYBEANS.
The process of bone formation. Histogenesis of bone including ossification.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Products in capsule, tablet or liquid form that provide dietary ingredients, and that are intended to be taken by mouth to increase the intake of nutrients. Dietary supplements can include macronutrients, such as proteins, carbohydrates, and fats; and/or MICRONUTRIENTS, such as VITAMINS; MINERALS; and PHYTOCHEMICALS.
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.
The measurement of the density of a material by measuring the amount of light or radiation passing through (or absorbed by) the material.
Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities.
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
Regular course of eating and drinking adopted by a person or animal.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The giving of drugs, chemicals, or other substances by mouth.
The application of suitable drug dosage forms to the skin for either local or systemic effects.
The region of the HAND between the WRIST and the FINGERS.
Native, inorganic or fossilized organic substances having a definite chemical composition and formed by inorganic reactions. They may occur as individual crystals or may be disseminated in some other mineral or rock. (Grant & Hackh's Chemical Dictionary, 5th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.
Excision of the uterus.
Injuries involving the vertebral column.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Diseases of BONES.
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.
The largest of three bones that make up each half of the pelvic girdle.
Physical activity which is usually regular and done with the intention of improving or maintaining PHYSICAL FITNESS or HEALTH. Contrast with PHYSICAL EXERTION which is concerned largely with the physiologic and metabolic response to energy expenditure.
Elements of limited time intervals, contributing to particular results or situations.
Falls due to slipping or tripping which may result in injury.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
Foods made from SOYBEANS. Health benefits are ascribed to the high levels of DIETARY PROTEINS and ISOFLAVONES.
An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system.
A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
A non-steroidal ESTROGEN generated when soybean products are metabolized by certain bacteria in the intestines.
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)
Material prepared from plants.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
Fractures of the short, constricted portion of the thigh bone between the femur head and the trochanters. It excludes intertrochanteric fractures which are HIP FRACTURES.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.
Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.
One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
Statistical models in which the value of a parameter for a given value of a factor is assumed to be equal to a + bx, where a and b are constants. The models predict a linear regression.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
Production of a radiographic image of a small or very thin object on fine-grained photographic film under conditions which permit subsequent microscopic examination or enlargement of the radiograph at linear magnifications of up to several hundred and with a resolution approaching the resolving power of the photographic emulsion (about 1000 lines per millimeter).
The relative amounts of various components in the body, such as percentage of body fat.
Endoscopic examination, therapy or surgery of the interior of the uterus.
Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
The technique that deals with the measurement of the size, weight, and proportions of the human or other primate body.
Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
Radiographic examination of the breast.
Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.
The joint that is formed by the articulation of the head of FEMUR and the ACETABULUM of the PELVIS.
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Studies in which variables relating to an individual or group of individuals are assessed over a period of time.
A range of values for a variable of interest, e.g., a rate, constructed so that this range has a specified probability of including the true value of the variable.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
Process by which organic tissue becomes hardened by the physiologic deposit of calcium salts.
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power.
An important aggregate factor in epidemiological studies of women's health. The concept usually includes the number and timing of pregnancies and their outcomes, the incidence of breast feeding, and may include age of menarche and menopause, regularity of menstruation, fertility, gynecological or obstetric problems, or contraceptive usage.
A group of twelve VERTEBRAE connected to the ribs that support the upper trunk region.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Therapy with two or more separate preparations given for a combined effect.
Typical way of life or manner of living characteristic of an individual or group. (From APA, Thesaurus of Psychological Index Terms, 8th ed)
Injuries to the part of the upper limb of the body between the wrist and elbow.
Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
The genital canal in the female, extending from the UTERUS to the VULVA. (Stedman, 25th ed)
The premature cessation of menses (MENSTRUATION) when the last menstrual period occurs in a woman under the age of 40. It is due to the depletion of OVARIAN FOLLICLES. Premature MENOPAUSE can be caused by diseases; OVARIECTOMY; RADIATION; chemicals; and chromosomal abnormalities.
Derivatives of the steroid androstane having two double bonds at any site in any of the rings.
Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.
A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
The relationship between the dose of an administered drug and the response of the organism to the drug.
Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.
The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.
Crumbling or smashing of cancellous BONE by forces acting parallel to the long axis of bone. It is applied particularly to vertebral body fractures (SPINAL FRACTURES). (Blauvelt and Nelson, A Manual of Orthopedic Terminology, 1994, p4)
Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A group of substances similar to VITAMIN K 1 which contains a ring of 2-methyl-1,4-naphthoquinione and an isoprenoid side chain of varying number of isoprene units. In vitamin K 2, each isoprene unit contains a double bond. They are produced by bacteria including the normal intestinal flora.
An annual legume. The SEEDS of this plant are edible and used to produce a variety of SOY FOODS.
Voluntary cooperation of the patient in following a prescribed regimen.
A cysteine protease that is highly expressed in OSTEOCLASTS and plays an essential role in BONE RESORPTION as a potent EXTRACELLULAR MATRIX-degrading enzyme.
Human males as cultural, psychological, sociological, political, and economic entities.
A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.
The frequency of different ages or age groups in a given population. The distribution may refer to either how many or what proportion of the group. The population is usually patients with a specific disease but the concept is not restricted to humans and is not restricted to medicine.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
X-RAY COMPUTERIZED TOMOGRAPHY with resolution in the micrometer range.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
6,17-Dimethylpregna-4,6-diene-3,20-dione. A synthetic progestational hormone with actions similar to those of progesterone. It is used in the treatment of menstrual irregularities and has also been employed in the treatment of prostatic hypertrophy and endometrial carcinoma.
A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.
Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.
Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base.
A tumor necrosis factor receptor family member that is specific for RANK LIGAND and plays a role in bone homeostasis by regulating osteoclastogenesis. It is also expressed on DENDRITIC CELLS where it plays a role in regulating dendritic cell survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.

Association of polymorphism at the type I collagen (COL1A1) locus with reduced bone mineral density, increased fracture risk, and increased collagen turnover. (1/1081)

OBJECTIVE: To examine the relationship between a common polymorphism within intron 1 of the COL1A1 gene and osteoporosis in a nested case-control study. METHODS: We studied 185 healthy women (mean +/- SD age 54.3+/-4.6 years). Bone mineral density (BMD) was measured using dual x-ray absorptiometry, and fractures were determined radiographically. The COL1A1 genotype was assessed using the polymerase chain reaction and Bal I endonuclease digestion. RESULTS: Genotype frequencies were similar to those previously observed and in Hardy-Weinberg equilibrium: SS 61.1%, Ss 36.2%, and ss 2.7%. Carriage of at least one copy of the "s" allele was associated with a significant reduction in lumbar spine BMD (P = 0.02) and an increased risk of total fracture (P = 0.04). Urinary pyridinoline levels were significantly elevated in those with the risk allele (P < 0.05). CONCLUSION: These data support the findings that the COL1A1 gene polymorphism is associated with low BMD and fracture risk, and suggest a possible physiologic effect on total body turnover of type I collagen.  (+info)

Immunoradiometric assay for intact human osteocalcin(1-49) without cross-reactivity to breakdown products. (2/1081)

BACKGROUND: Osteocalcin (Oc), a serum marker of bone turnover, circulates in several forms. We developed an assay for intact human Oc and investigated its clinical features. METHODS: We generated goat antibodies and N- and C-terminal Oc. The former was used on solid phase (polystyrene beads), and the latter was used as the tracer in an IRMA. RESULTS: The assay was linear with no cross-reactivity to Oc(1-43), total imprecision (CV) of <10%, and recovery of 100% +/- 10%. Assay values for intact Oc in EDTA plasma samples were unchanged at 18-25 degrees C for 6 h. Values for intact Oc in serum, EDTA plasma, and heparin plasma samples did not change after storage on ice for 8 h. Serum samples from patients with various conditions were stored at -70 or -135 degrees C for up to 5 years and yielded z-scores comparable to an Oc(1-43) IRMA for all conditions except for renal failure. In renal failure, the Oc(1-43) assay values were increased, whereas the intact assay values were in the reference interval. CONCLUSION: Decreases in Oc assay values are inhibited by calcium chelation, and slowed by reduced temperatures. The described assay for intact Oc allows improved specificity for bone compared with an assay for Oc(1-43).  (+info)

Health screening in older women. (3/1081)

Health screening is an important aspect of health promotion and disease prevention in women over 65 years of age. Screening efforts should address conditions that cause significant morbidity and mortality in this age group. In addition to screening for cardiovascular disease, cerebrovascular disease and cancer, primary care physicians should identify risk factors unique to an aging population. These factors include hearing and vision loss, dysmobility or functional impairment, osteoporosis, cognitive and affective disorders, urinary incontinence and domestic violence. Although screening for many conditions cannot be proved to merit an "A" recommendation (indicating conclusive proof of benefit), special attention to these factors can decrease morbidity and improve quality of life in aging women.  (+info)

Effects of single and concurrent intermittent administration of human PTH (1-34) and incadronate on cancellous and cortical bone of femoral neck in ovariectomized rats. (4/1081)

The purpose of this study is to determine the efficacy of concurrent treatment with human parathyroid hormone, hPTH (1-34), and bisphosphonate (incadronate) in augmenting cortical and cancellous bone mass of femoral neck in ovariectomized (OVX) rats. Forty-eight 11-week-old female Sprague-Dawley rats were divided into eight groups (six animals in each group). The baseline control group was killed at the beginning of the experiment, at 11 weeks of age. An ovariectomy was performed in thirty rats and twelve rats were subjected to a sham surgery. OVX rats were untreated for the first four weeks of postsurgery to allow for the development of moderate osteopenia. These animals were then subjected to various treatments with either PTH, incadronate, or PTH+ incadronate for a period of 4 weeks. Right proximal femora (femoral necks) were used for bone histomorphometry. After OVX 8 weeks, there was a significant decrease in cancellous bone mass and cortical bone area of femoral neck in the OVX rats when compared to the sham control rats. In OVX rats treated with PTH alone or PTH+ incadronate were completely restored lost cancellous and cortical bone mass of femoral neck by increase bone formation. The bone formation parameters (OS/ BS, MS/BS) and bone turnover (BFR/BV) seen with PTH plus incadronate were similar to those seen with PTH treatment alone. This indicates that incadronate did not blunt the anabolic action of PTH when used concurrently. Our results suggest the followings: 1) the femoral neck of OVX rats is a suitable sample site for preclinical studies of the prevention of bone loss induced by estrogen depletion; 2) concurrent use of incadronate did not blunt the anabolic effect of PTH; 3) concurrent treatment showed the best results in restoring cancellous and cortical bone mass; and 4) it had additional benefits for bone strength independent of that achieved by the increase in bone mass.  (+info)

Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. (5/1081)

Declining estrogen levels during the first postmenopausal decade lead to rapid bone loss and increased fracture risk that can be reversed by estrogen replacement therapy. The bone-protective effects of estrogen may involve suppression of inflammatory cytokines that promote osteoclastogenesis and bone resorption, such as IL-1, TNF-alpha, and IL-6. We investigated whether estrogen modulates IL-1 actions on human osteoclasts (OCs) and other bone cell types. Isolated human OCs and primary bone marrow-derived OC-like cells expressed both the signaling (IL-1RI) and decoy (IL-1RII) IL-1 receptors, whereas only IL-1RI was detected in osteoblasts. IL-1RII/IL-1RI mRNA ratios and release of soluble IL-1RII (sIL-1RII) were lower in OC-like cells derived from women in the late postmenopausal period compared with younger women, but were unrelated to male donor age, suggesting that estrogen might play a role in regulating IL-1 receptor levels in vivo. Estrogen directly reduced in vitro OC-like cell IL-1RI mRNA levels while increasing IL-1RII mRNA levels and sIL-1RII release. These estrogenic events were associated with inhibited IL-1-mediated cytokine (IL-8) mRNA induction and cell survival, i.e., increased apoptosis. In contrast, estrogen did not alter IL-1R levels or IL-1 responsiveness in primary human osteoblasts or bone marrow stromal cells. We conclude that one novel mechanism by which estrogen exerts bone-protective effects may include a selective modulation of IL-1R isoform levels in OC or OC-like cells, thereby reducing their IL-1 responsiveness and cell survival. Conversely, this restraint on IL-1 actions may be lost as estrogen levels decline in aging women, contributing to an enhanced OC-mediated postmenopausal bone loss.  (+info)

Habitual physical activity and bone mineral density in postmenopausal women in England. (6/1081)

BACKGROUND: Reduced levels of physical activity have been found to be associated with an increased risk of osteoporotic fracture in a number of epidemiological studies, and intervention studies have shown beneficial effects of exercise regimes on bone mineral density. It is not yet established, however, which specific forms of customary physical activity are most strongly associated with bone mineral density in postmenopausal women. METHODS: A cross-sectional study was conducted in 580 postmenopausal women, aged 45-61 years, resident in Nottingham, England. The participants completed a detailed interviewer-administered activity questionnaire. Physical activity was assessed as total hours of participation per week in activities including housework, walking, gardening and sports. Stair-climbing and self-reported walking pace were also reported. Bone mineral density measurements were made using dual energy x-ray absorptiometry, measurements at five sites were used in analysis. RESULTS: The strongest associations between the activity measures and bone mineral density were for stair-climbing and walking pace, which both gave statistically significant positive associations at the trochanter hip site and the whole body. In women reporting a fairly brisk or fast walking pace, bone mineral density at the proximal femur was also significantly and positively associated with the frequency of walking at least a mile. There were no significant associations with aggregate measures of total customary physical activity. CONCLUSIONS: This study has identified two forms of physical activity, namely stair-climbing and brisk walking which are associated with increased bone mineral density at the hip and whole body in postmenopausal women. Both are feasible forms of activity for promoting to middle-aged women.  (+info)

Association of race and other potential risk factors with nonvertebral fractures in community-dwelling elderly women. (7/1081)

This study determined potential associations of sociodemographic, lifestyle, health, and drug use factors known to affect bone metabolism with incident nonvertebral fractures. The baseline sample consisted of 2,590 female, nonproxy subjects from the Duke Established Populations for Epidemiologic Studies of the Elderly, which focuses on five adjacent counties in the Piedmont area of North Carolina. Information about potential risk factors was collected during a baseline in-home interview during 1986-1987. Subsequent nonvertebral fractures were reported at follow-up interviews during the annual follow-up periods (1988-1993). The authors used multivariate analyses in which weighted data were adjusted for sampling design. After controlling for other potential confounding sociodemographic, lifestyle, health, and drug use factors, they found that African American race (adjusted odds ratio (OR) = 0.43, 95% confidence interval (CI) 0.31-0.58), age (adjusted OR = 1.04, 95% CI 1.01-1.06), alcohol consumption (adjusted OR = 1.61, 95% CI 1.01-2.57), being underweight (adjusted OR = 1.63, 95% CI 1.13-2.34), cognitive impairment (adjusted OR = 1.67, 95% CI 1.12-2.48), impaired mobility (adjusted OR = 1.15, 95% CI 1.03-1.29), and phenytoin use (adjusted OR = 2.93, 95% CI 1.04-8.30) were associated with first fracture occurrence. Similar findings were observed for nonhip, nonvertebral fractures. African Americans were less likely than Whites to have nonvertebral fractures, and these differences were not related to lifestyle or health factors examined in this study.  (+info)

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. (8/1081)

OBJECTIVE: To investigate whether the incidence of vertebral fractures is related to the magnitude of change in bone mineral density (BMD) during alendronate treatment. METHODS: Women in this study were age 55-81 years (n = 2,984). While participating in the Fracture Intervention Trial, they received 5 mg/day of alendronate for 2 years followed by 10 mg/day for the remaining 12-30 months of the study. Their BMD was measured at baseline and at 12 and 24 months, and spine radiographs were obtained at baseline and again at 36 or 48 months to identify new vertebral fractures. RESULTS: After 12 months of alendronate treatment, 35% of participants had increases of > or =3% in total hip BMD, and 21% had either decreased total hip BMD or no change. Women who had larger increases in total hip BMD during the first 12 months had a lower incidence of new vertebral fractures during the entire followup period. Only 3.2% of women with increases of > or =3% in total hip BMD experienced new vertebral fractures, whereas twice as many women (6.3%) whose BMD declined or stayed the same experienced new fractures (adjusted odds ratio 0.45, 95% confidence interval 0.27-0.72). Similar patterns were observed for spine BMD at 12 months, and for both sites using change in BMD at 24 months. CONCLUSION: Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures. These findings suggest that, among women taking antiresorptive agents, greater increases in BMD are associated with lower risk of new vertebral fractures.  (+info)

TY - JOUR. T1 - Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. AU - Miller, Paul D.. AU - Delmas, Pierre D.. AU - Huss, Hermann. AU - Patel, Katie M.. AU - Schimmer, Ralph C.. AU - Adami, Silvano. AU - Recker, Robert R.. PY - 2010/10/1. Y1 - 2010/10/1. N2 - The relationship between bisphosphonate-induced bone mineral density (BMD) gains and antifracture efficacy remains to be fully elucidated. Data from two antifracture studies were analyzed. Postmenopausal osteoporotic women received oral (2.5 mg daily, 20 mg intermittent) or intravenous (0.5 mg, 1 mg quarterly) ibandronate. Outcome measures included moving averages plots and logistic regression analyses of the relationship between BMD change and vertebral fracture rate. In moving averages plots, ibandronate-induced BMD gains were consistently associated with decreased fracture rates. In the oral study, total-hip BMD increases at years 2 and 3 and lumbar spine BMD increases ...
OBJECTIVE: To compare the performance of raloxifene and strontium rannelate in the management of women with postmenopausal osteoporosis.. DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). Participants were followed for 1 year.. MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers. ...
TY - JOUR. T1 - Axial BMD, change in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women. AU - Stewart, Alison. AU - Kumar, A.. AU - Torgerson, D. J.. AU - Fraser, W. D.. AU - Gilbert, Fiona. AU - Reid, David M. PY - 2005/12. Y1 - 2005/12. N2 - Previous studies have indicated a relationship between bone mineral density and the incidence of breast cancer in middle-aged and elderly women, with women with higher BMD being at significant increased risk. We investigated whether there was such a relationship in younger women who were perimenopausal or in their early postmenopausal years. As part of a population-screening program for osteoporosis, 5,119 women aged between 45 and 54 years were scanned between 1990-1994 at the Osteoporosis Research Unit. In 1997-2001, 3,884 returned for follow-up scans and questionnaires, and 3,144 returned a postal questionnaire in 2002. All cases of incident breast cancer were noted. One hundred sixty-six women indicated that they ...
A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis. Patients will be randomized into either 1) a group which receives bone marker feedback or 2)a group which does not receive feedback on the results. The study will also assess patient satisfaction with treatment with once monthly Bonviva. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals ...
A trend to watch in the postmenopausal osteoporosis drugs market is the emergence of novel agents. There have been encouraging developments in the postmenopausal osteoporosis drug
Ipriflavone is a synthetic isoflavone derivative, which has been suggested to be an inhibitor of bone resorption and a stimulator of osteoblast activity in vitro in cell cultures and in vivo in experimental models of osteoporosis. Preliminary studies, mainly performed in Italy and Japan, suggested that ipriflavone (typical dosage 600 mg/day) is able to prevent bone loss, and some data even suggested that ipriflavone may increase bone mass in postmenopausal women. However, reports of lymphocytopenia in women taking ipriflavone generated concerns regarding the safety of this particular compound. In order to investigate the effect of oral ipriflavone in prevention of postmenopausal bone loss and to assess the safety profile of long-term treatment with ipriflavone in postmenopausal osteoporotic women, a prospective, randomized, placebo-controlled 4-year study was conducted in 474 postmenopausal white women with bone mineral densities below the threshold for a diagnosis of osteoporosis, according to ...
Background-The differences in the incidence of heart failure (HF) by race/ethnicity as well as the potential mechanisms for these differences are largely unexplored in women. Methods and Results-155,335 post menopausal women free of self-reported HF enrolled from 1993-1998 at 40 clinical centers throughout the United States as part of the Womens Health Initiative and were followed until 2005, for an average of 7.7 years for incident hospitalized heart failure. Incident rates, hazards ratios and 95% CI were determined using Cox-proportional hazards model comparing racial/ethnic groups and population attributable risk percentages were calculated for each racial/ethnic group. African Americans had the highest age-adjusted incidence of HF (405/100,000 person-years) followed by whites (283) Hispanics (191) and Asian/Pacific Islanders (102). The excess risk in African Americans compared to whites (age-adjusted HR= 1.47) was significantly attenuated by adjustment for household income (HR=0.99) and ...
TY - JOUR. T1 - Estrogens and postmenopausal osteoporosis. AU - Heaney, R. P.. PY - 1976. Y1 - 1976. N2 - I have outlined a comprehensive model of estrogen action on bone that explains the known physiologic effects of estrogen and that is consistent with the limited data of the available clinical studies. I cannot stress too highly that the model, however elegant and satisfying, is not the same as real postmenopausal women. The predictions of the model can be tested only in that world. Special problems make this testing unusually difficult, but the disease is too important in a population with the current and changing age distribution in the United States to excuse additional delay in undertaking the necessary studies. If the model is valid, it suggests that estrogen has a role in treatment of osteoporosis, but only if that treatment is confined strictly to palliation. The model also suggests that estrogen may play a much more important role in prevention. But to whom should such prevention be ...
MELBOURNE, Australia -- A fracture risk score for osteoporotic women may help clinicians decide how to proceed when multiple-site bone mineral density measurements disagree, researchers said.
This article describes the adaptation of a model estimating the burden of postmenopausal osteoporosis (PMO) to the UK. The purpose of this study was to estimate the present and future epidemiology of
Osteoporosis study examining how submaximal aerobic exercise affects bone metabolism and balance. Should you be recommending a certain type of aerobic exercise to your postmenopausal osteoporotic patients?
Background & Aims: Osteoporosis is the most common metabolic bone disease. The aim of this study was to investigate the effects of exercise therapy on balance, muscle strength, bone density and quality of life in women with primary osteopenia and osteoporosis and to compare two types of aerobic and strengthening ...
What did the study find?. This review of studies reviews studies totaling 619 women between the age of 36-75 and found supplementation of calcium to be safe and effective for the prevention of osteoporosis. ...
See your MD. Usually you want to develop a combination of calcium and vitamin d to help prevent osteopososis. You first need a baseline to see if you are at risk.Then your gyn or endocrinologist can help you determine what is best for you. Good thinking ! good luck ...
white race, not restless, no vaginal dryness, relative with prostate cancer, colon polyps, smoking, no breast augmentation, and no osteoporosis. Risk factors previously reported that were not independently associated with breast cancer in the present study included socioeconomic status, months of breast feeding, age at first birth, adiposity measures, adult weight gain, timing of initiation of hormone therapy, and several dietary, psychological, and exercise variables. Family history was not found to alter the risk associated with other factors. ...
en] Postmenopausal osteoporosis is characterized not only by a reduction in bone mass but also by bone microarchitecture alterations, which result in greater bone frailty and in an increased fracture risk. Many drugs have been studied to determine whether they prevent bone loss or reduce the incidence of additional fractures in patients with established osteoporosis. Primary prevention of osteoporosis rests on regular exercising and adequate intake of dietary calcium. For secondary prevention in women undergoing menopause, replacement estrogen therapy given for at least ten years is associated with substantial reductions in fractures of the radius, hip, and spine. Other drugs capable of arresting postmenopausal bone loss include parenteral, nasal or rectal calcitonin and diphosphonates. However, the long-term safety of the latter requires further evaluation. Current studies are evaluating new molecules with potential preventive efficacy, such as ipriflavone. There is no general consensus about ...
Você precisa iniciar uma sessão de usuário para visualizar esta página. Por favor, Faça login. Você ainda não possui uma conta de usuário? Cadastre-se! ...
My research is mainly focused on the effects of cholesterol, saturated fat and statin drugs on health. If you know anyone who is worried about their cholesterol levels and heart disease, or has been told to take statin drugs you could send them a link to this website, and to my statin or cholesterol or heart disease books ...
Youll hear about Evenity (ee-VEN-ih-tee, romosozumab), a new injectable med for postmenopausal women with osteoporosis.... Learn more with Hospital Technicians Letter.
Health, ...Post-menopausal women who engage in moderate to vigorous exercise have... With an estimated 182460 new cases diagnosed in the United States in...Over 110000 post menopausal women were asked to rate their level of p...Dr. Peters concludes Our findings could help inform the mechanisms o...,Recent,,vigorous,exercise,is,associated,with,reduced,breast,cancer,risk,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The WHI CaD study is the largest study ever conducted on calcium supplementation reported in the New England Journal of Medicine, followed over 36,000 post menopausal women for 7 years. Half the women took 1,000 mg of Calcium & 400 IU of Vitamin D daily; the other half took a placebo. The study showed that women taking placebos had a fracture rate (indicator of bone density) of 14/10,000. The fracture rate for women taking supplements was only 10/10,000. While the trend is favorable, the message of the study is that Calcium & Vitamin D are not enough, reported Dr. Joel S. Finkelstein, an osteoporosis researcher at the Massachussets General Hospital in Boston ...
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).
I am a 45 year old female. I have had 5 children with all pregancies being normal. Over the last year I have experienced some bleeding problems. Earlier this year I had a spot on my cervix that needed to be frozen to prevent bleeding mid cycle. I have noticed also that my periods have become heavier especially the first full day of bleeding. I have just made a point of staying close to a bathroom on those days. However this past month I began my period and it was so bad that within 2 days I became anemic. My gyn prescribed Medroxyprogesterone for 10 days. Now 22 days later I have what appears to be a very heavy period again. My Dr. again prescribed another 10 days of progesterone and said that we should try this for a few months to see if it will help. Quite frankly Im not sure that this therapy makes sense to me. Ive read that progesterone is for post menopausal women or if your period is irregular and you do not get it. I have had 2 negative biopsies so there is no sign of trouble to cause ...
Bio-identical oestrogen has many benefits for long term health in post -menopausal women. Different strengths are customised to suit each individual woman.
This extension study investigated the tolerability of denosumab [AMG 162] in women with postmenopausal osteoporosis who completed the FREEDOM trial.This study
Circulatory osteocalcin (OC) has been widely used as a biomarker to indicate bone turnover status in postmenopausal osteoporosis (PMO). However, the change of serum OC (sOC) level in PMO cases compared to postmenopausal controls remains controversial. We searched the online database of PubMed and Cochrane Library. A meta-analysis of case-control studies was performed to compare the pooled sOC level between PMO patients and postmenopausal controls. Subgroup analysis according to potential confounding factors (different OC molecules and regions of the study population) was also performed. Ten case-control studies with 1577 postmenopausal women were included in this meta analysis. We found no significant difference in the pooled sOC level [mean difference (MD) = 1.84, 95% confidence interval (CI): (− 1.49, 5.16), p = 0.28] between PMO patients and controls. Subgroup analysis also revealed no significant difference in intact OC [MD = 1.76, 95%CI: (− 1.71, 5.23), p = 0.32] or N-terminal mid-fragment of
Although widely used for its anti-estrogen properties tamoxifen has estrogen like effects on a number of tissues including bone and liver. Previous studies suggest a preservation of lumbar spine density in postmenopausal women but the effect on the hip had not been addressed. To determine whether tamoxifen prevents bone loss in the early postmenopausal period bone mineral density at the lumbar spine and femoral neck was measured using dual energy X-ray absorptiometry at presentation and 6 monthly thereafter for 1 year in a prospective controlled study. Also indices of bone turnover, serum osteocalcin and urinary hydroxyproline excretion, were assessed. Fifteen early postmenopausal women with Stage I or II breast cancer treated with tamoxifen and 21 normal postmenopausal women were studied. Sex hormone binding globulin and antithrombin III levels in serum were also measured as indices of the hepatic estrogenic activity. Tamoxifen (20 mg daily) prevented bone loss at the femoral neck and lumbar spine.
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTRODUCTION: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of |2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens. MATERIALS AND METHODS: MOBILE is a 2-year, randomized, double-blind,
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis Jun Iwamoto1, Mitsuyoshi Uzawa2, Yoshihiro Sato3, Tsuyoshi Takeda1, Hideo Matsumoto11Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan; 3Department of Neurology, Mitate Hospital, Fukuoka, Japan Abstract: The antiresorptive drug elcatonin (ECT) is known to relieve pain in postmenopausal women with osteoporosis. A prospective open-labeled trial was conducted to compare the effects of short-term combined treatment with alendronate (ALN) and ECT on bone mineral density (BMD) and bone turnover with those of single treatment with ALN in postmenopausal women with osteoporosis. Two hundred and five postmenopausal osteoporotic women (mean age: 70 years) were recruited in our outpatient clinic. Forty-six women with back pain were treated
Definition of simple calculated osteoporosis risk estimation in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is simple calculated osteoporosis risk estimation? Meaning of simple calculated osteoporosis risk estimation as a finance term. What does simple calculated osteoporosis risk estimation mean in finance?
Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the United States with osteoporosis are women. One out of every two women over age 50 will break a bone in their lifetime due to osteoporosis.. People with osteoporosis at high risk for fracture include those that have had an osteoporotic fracture, or have multiple risk factors for fracture; or those who have failed or are intolerant to other available osteoporosis therapy. Prolia works to decrease the destruction of bone and increase bone mass and strength. An injection of Prolia is recommended once every six months.. Due to its prevalence, osteoporosis is a serious concern to public health, said Julie Beitz, M.D., director of the FDAs Office of Drug Evaluation III. The approval of Prolia provides another treatment option for postmenopausal women with osteoporosis who are susceptible to ...
Objective: Estrogen deficiency probably induces increase of some cytokines (IL-1β, IL-2, IL-6, IL-8, TNF-α) that play role in bone resorption. The aim of our study was to determine the role of the cytokines in the etiopathogenesis of postmenopausal OP and its relationship with estrogen level, bone mineral density and bone turnover markers.. Patients and Methods: The study group consisted of 108 subjects, 72 postmenopausal and 36 premenopausal women aged 30-85 years. The postmenopausal women were divided into 2 groups according to the presence of osteoporosis. Serum levels of cytokines (IL-1β, IL-2, IL-6, IL-8, TNF-α), estrogen, osteocalcin and urinary levels of deoxypyridinoline (DOP) were measured. Bone mineral density (BMD) of the lumbar spine and femur neck were measured by dual-energy X-ray absorbtiometry (DEXA).. Results: Generally a decrease in estrogen level and an increase in cytokine production were observed in postmenopausal women. There was no significant differences between the ...
the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. 2. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24. 3. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention 4. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-90. 5. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97. 6. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer ...
May 17, 2004. Strontium ranelate can prevent both hip and vertebral fractures in women over 70 years old, researchers reported this week at the IOF World Congress on Osteoporosis in Rio de Janeiro (conference abstract OC 39).. Women in this age bracket have an elevated risk of sustaining hip fractures, which have been shown to increase mortality at the rate of 15 to 30 percent, mostly within the first six months after the fracture. Data show that two grams of strontium ranelate, taken daily, can reduce the risk of hip fractures in this subpopulation by 36%, and vertebral fractures by up to 59%.. The bone-saving properties of strontium ranelate were evaluated in two randomized, double-blind, placebo controlled trials. The five-year TROPOS (TReatment Of Peripheral OSteoporosis) study was designed to evaluate the efficacy of the drug in treating peripheral fractures, while the Spinal Osteoporosis Therapeutic Intervention (SOTI) study was designed to assess the drugs ability to reduce new vertebral ...
The Osteoporosis Prevention and Treatment Center specializes in the prevention, diagnosis and treatment of osteoporosis and metabolic bone disease, including postmenopausal osteoporosis, male osteoporosis, osteopenia induced by glucocorticoids, anticonvulsants and excess thyroid hormone; Pagets disease, hypercalcemia of malignancy, and hyperparathyroidism.
Ibandronate, a potent bisphosphonate currently under clinical investigation for the treatment and prevention of osteoporosis in post-menopausal women, was shown to reduce new vertebral fractures, according to data presented here at the 24th annual meeting of the American Society for Bone and Mineral Research (ASBMR). Based on findings from the large, multinational study,1 ibandronate is the first bisphosphonate shown to reduce new vertebral fractures with a between dose interval of greater than two months, holding promise for development of new convenient, less frequent dosing regimens. Ibandronate is under joint development by Roche and GlaxoSmithKline. Results presented from BONE, a three-year, pivotal phase III trial in more than 2,900 women with postmenopausal osteoporosis showed oral 2.5 mg daily ibandronate reduced the risk of new vertebral fractures by 62 percent compared with placebo. In addition, study results showed an intermittent (20 mg) dose of oral ibandronate taken every other day ...
It is important to speak to your healthcare provider to find out when a BMD test is appropriate for you. Your healthcare provider will consider your risk factors for osteoporosis (such as your age, medical history including your history of broken bones, your parental history of osteoporosis and/or fracture, and more) when deciding on the right time for you to have a BMD test.. The NYSOPEP Osteoporosis Risk Assessment for Postmenopausal Women is a tool that you can use to identify your personal risk factors for osteoporosis. The completed assessment should be discussed with your healthcare provider. The tool can be used to empower your discussion with your healthcare provider about how to reduce your risks for osteoporosis and help your healthcare provider decide when a BMD test is right for you. Although risk factors may increase your likelihood of getting osteoporosis, having risk factors does not mean that you have or will get the disease. A BMD test is the only way to diagnose ...
Background: Vitamin D popularly known as sunshine vitamin is both vital and indispensable for human beings. It caters to skeletal as well as non skeleta..
Osteoporosis was first discovered by John Hunter, British surgeon, in 1800s. Osteoporosis may be classified as primary or secondary, based on etiology; while, it is divided in to osteopenia, osteoporosis, and severe osteoporosis, based on disease severity. Osteoporosis occurs as result of an imbalance between bone resorption and bone formation. Major contributing factors to the development of osteoporosis include estrogen deficiency and aging. These factors might lead to osteoporosis by reactive oxygen species (ROS) mediated damage to osteocytes. Decrease in the capability of autophagy in osteocytes is another important factor which makes them vulnerable to oxidative stress. Genes involved in the pathogenesis of osteoporosis can be categorized in four main groups which include the osteoblast regulatory genes, osteoclast regulatory genes, bone matrix elements genes, and hormone/receptor genes. Osteoporosis must be differentiated from other diseases associated with a decrease in bone mineral ...
Osteoporosis is disease that leads to embrittlement of bones that occurs as a result of reduction in density, as well as changes in the structure of bones. Every other woman and every fifth man is at risk of experiencing a fracture caused by osteoporosis. Small injuries, which in healthy young person would not lead to fractures, often lead to fractures of the hip, spine, or forearm in people with osteoporosis. In women, osteoporosis occurs at menopause, so it is called postmenopausal osteoporosis. During menopause, womans ovaries cease to produce estrogen, which protects the bones. This initiates the process of rapid bone loss.. Fortunately, you can take certain steps to reduce the risk of osteoporosis and prevent serious fractures that occur as a result of this disease.. ...
TY - JOUR. T1 - Reproductive hormone exposure timing and ischemic heart disease. T2 - Complicated answers to a simple question. AU - Bairey Merz, C. Noel. AU - Shufelt, Chrisandra. AU - Johnson, B. Delia. AU - Azziz, Ricardo. AU - Braunstein, Glenn D.. PY - 2010/4/1. Y1 - 2010/4/1. N2 - The current literature, combined with improved methodology in the WISE study, suggests that there is a beneficial relation between HT use and IHD in peri- and early postmenopausal women. Our results are also consistent with recent clinical trials that have failed to show benefit of HT initiation in older postmenopausal women, either for angiographic coronary disease or cardiac events. Overall, our data suggest that the anti-atherosclerotic effect of HT, if present, may be age-dependent and primarily evident in relatively younger peri- and early postmenopausal women.. AB - The current literature, combined with improved methodology in the WISE study, suggests that there is a beneficial relation between HT use and ...
Almost all studies assessing the paracrine mediation of estrogen action have been made in rodents or use human bone cell lines or primary cultures of cells from orthopedic samples in vitro. Thus far, estrogen-regulation of bone marrow cytokines has not been studied directly in humans despite evidence that estrogen action on bone may differ substantially in humans and mice. For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32). Another, and possibly more relevant, example is that IL-6 consistently upregulates RANKL in murine cells in vitro (33), but fails to do so in human cells (34).. Our major objective was to determine whether expression of RANKL by bone marrow cells contributes to the increased bone resorption in early postmenopausal women. Thus, in estrogen-deficient and estrogen-replete women, we obtained bone marrow mononuclear cells, used ...
I am a 60-year-old female with osteoporosis. I took Fosamax 70 mg once weekly for seven months until I could no longer endure the side effects. For the following month, I took no medication. Since January 21, 2008, I have been on 680 mg strontium citrate once daily. I intend to relate my progress. My first DEXA scan was done May 8, 2007. My T-score at the lumbar spine was -3.0 (-2.0 at L1, -2.7 at L2, -3.4 at L3 and -3.8 at L4). My T-score at the left hip was -2.2 (-2.8 at neck, -2.0 at troch, -1.9 at inter). My BMD results in g/cm2 were 0.712 at the spine (L1-L4), 0.53 at the left hip (neck), and 0.670 at the left hip (total). A followup scan is planned for July 6, 2009. For these results, see: http://strontiumforbones.blogspot.com/2009/07/improved-t-scores-after-treatment. ...
1. Morohashi T, Sano T, Yamada S (1994) Effects of strontium on calcium metabolism in rats. I. A distinction between the pharmacological and toxic doses. Jpn J Pharmacol 64:155-162 2. Marie PJ, Garba MT, Hott M, Miravet L (1985) Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab 11:5-13 3. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on therisk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459-468 4. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelatereduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment ofperipheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816-2822 5. Blake GM, ...
According to a survey, more than 25 million Indians suffer from Osteoporosis. It is a common bone problem in the elderly people, which occurs due to the reduction in the bone density and bone strength. In osteoporosis, the bone becomes thin and porous, becoming more fragile and susceptible to fracture. The most common areas of osteoporosis related fracture are wrist, ribs, spine, and hips. Osteoporosis is more common in women than in men, particularly above the age of 60.
the promotion of exercise through brisk-walking advice given by nursing staff may have a small, but clinically important, impact on bone mineral density but is associated with an increased risk of falls. Self-paced brisk walking is difficult to evaluate in randomized controlled trials because of dro …
How Osteoporosis Could Affect the Way You Practice. Osteoporosis is a condition that can strike even the most health-conscious and vibrant of your patients. Here is what you need to know about the condition.. Osteoporosis is a condition in which bones become thin and less dense over time; as bone mineral density is reduced, the amount and variety of proteins in bone changes and the bone micro-architecture is disrupted.1 In osteoporosis, the bone loss is severe, causing even the normal stress that occurs during sitting, standing, or even coughing to cause unexpected fractures. As a result, it is not uncommon for someone with osteoporosis to struggle with chronic pain, immobility, disability, loss of independence, and a lower quality of life.2,3. What Are the Symptoms?. Osteoporosis occurs stealthily over several years with no visible signs. Often, the first sign of osteoporosis is a painful fracture that needs medical care. The bones most susceptible to fracture are the spine, hip, rib, or ...
Higher estradiol doses had significant benefits for cardiovascular risk factors in early postmenopausal women, but these effects were attenuated in late postmenopausal women.
Osteoporosis is a major health threat in the United States, particularly among people older than 50 years of age. Estimates indicate that 10 million Americans have osteoporosis, and another 34 million are at risk of developing osteoporosis due to low bone mass. Although women are more at risk of developing the condition (80% of patients with osteoporosis are women), all people older than 50 should be concerned about prevention, because studies indicate that 55% of Americans older than 40 exhibit signs of low bone mass. The best way to fight osteoporosis is with early intervention - ideally in the form of a calcium-rich diet and weightbearing exercise. Men younger than 65 and premenopausal women should be getting 1000 mg of calcium a day, and men and women aged 65 and older should be getting a daily dose of 1500 mg. The problem is that most people do not consume a diet of the dairy products, leafy green vegetables, fish, and tofu that delivers adequate levels of calcium. Thus, many patients are ...
|p|JTCM June 2004 76/51|br /|Diseases - Musculoskeletal|/p||p||em|(Archive subscribers please click on find out more to see abstract. The full article is not available online and must be bought as a photocopy delivered by post).|/em||/p|
What to take with vitamins to fight osteoporosis even better Ive had awesome results treating osteoporosis with diet and supplements. Ive told you about these treatments in the past. (You can see these past issues on my website.) Now I have yet more wonderful news. Theres a simple and cheap way to treat osteoporosis that could make my diet and supplement recommendations even more effective. Weve known for some time that osteoporosis has a link to inflammation. In fact, a recent study confirmed what Ive said for years. It showed that vitamin C (1,000 mg daily) and vitamin E (600 mg daily) can reduce inflammation and stop osteoporosis! The participants took the vitamins for six months. The researchers found the vitamins protected their bones as effectively as resistance training (three times per week). Lumbar spine bone loss essentially halted. The supplements worked as well as resistance training. And combining them did not add to the effectiveness.
The Osteoporosis Risk Assessment Instrument (ORIA) can be used to select women for bone densitometry. This can help reduce the number of women who are screened so that resources can be used for those at risk. The authors are from several medical institutions in Toronto including the University of Toronto.
If the doctor suspects osteoporosis, he or she will talk to the person and do an examination. The doctor will order X-rays of the patients bones as well as a bone density test.. Once the doctor is sure of osteoporosis, he or she will treat the patient to prevent more bone loss. Usually, someone with osteoporosis has to take medications that help slow down bone loss and should also take calcium supplements.. Diet and exercise are important parts of osteoporosis treatment. People need a variety of healthy, calcium-rich foods and regular exercise, such as walking or running, to strengthen bones. A doctor may also recommend weight training or special exercises. The person also will need to be careful to avoid falls, so avoiding icy sidewalks and other hazards is a good idea.. ...
Osteoporosis What is the best and safest treatment for osteoporosis?, What is the best natural treatment for osteoporosis?, How do you treat osteoporosis naturally?, What not to eat if you have osteoporosis?, Is sitting bad for osteoporosis?, What not to
Osteoporosis is a bone disease characterized by decrease in bone mass and density resulting in brittle, Dr. Jaspal treated for this condition in New York
The treatment of osteoporosis consists of lifestyle measures and pharmacologic therapy. An overview of the approach to therapy of osteoporosis in postmenopausal women will be presented here. The diagnosis and evaluation of osteoporosis in postmenopau
If youve been diagnosed with osteoporosis or osteopenia, physical therapy can help prevent a future bone injury. Osteoporosis is the gradual loss of bone density and weakening of the structure of the bones in the body. Osteopenia, a precursor to osteoporosis, refers to below normal bone mass.
Author(s): Sebastian, Anthony; Frassetto, Lynda A | Abstract: Osteoporosis is a disorder of bone in which the mass of the bone is reduced and the bones architecture at the microscopic level is disordered. Together those abnormalities predispose affected individuals to experience fractures despite only minimal trauma (i.e., fragility fractures). Age related osteoporosis is a common type of osteoporosis that occurs with aging in both men and women usually beginning after the age of peak bone mass. Research has found that the disorder can be partially reversed by reducing the net amount of acid that is produced when consuming typical Western diets. However, the amelioration that results has not been so dramatic or so consistent that physicians have adopted the procedure as part of the standard treatment for age-related osteoporosis. We propose that reducing the net acid load from the diet is not sufficient to reverse age related osteoporosis because it fails to supply base needed to restore the large
The two major determinants of risk in the development of osteoporosis are peak bone mass and rate of bone loss. These two determinants are influenced by a number of genetic and environmental factors. Roughly 70% of cases of osteoporosis are probably as a result of genetic predisposition, including the role of genetics in dictating how an individual will respond to exogenous stressors. The remaining 30% of cases probably triggered by environmental factors. In this study we intend to study prevalence of osteoporosis in the different population groups greater than 40 years age and identify risk factors associated with osteoporosis in them.. Materials and methods:. Five hundred persons of either sex of more than 40 years age group were analyzed with the help of Achilles express (calcaneal ultrasonometer) based upon their -T score. Detailed history of each person as referred to their Age, Sex and Marital status whether married or unmarried was recorded. Persons were analyzed based upon their ...
Evista (raloxifene) reviews from people of your age and gender for uses like Post-menopausal osteoporosis and Breast cancer prevention
NorthShore encourages patients to utilize our medical library. Read our Osteoporosis Risk Factors encyclopedia resources online.
Osteoporosis diagnosis, treatments and osteoporosis drugs. Osteoporosis prevention, treatment, calcium, bone density. Calcium supplements, Fosamax, Actonel, Miacalcin and other treatments. Osteoporosis made easy with pictures of fractures, bones, hormones, etc.
bone tissue.. Exercise can help prevent osteoporosis, a serious disease in which your bones become brittle, weak and may even break easily. Although post-menopausal women are at a higher risk for osteoporosis, anyone can develop it, so taking actions to avoid it is good for everyone.. Some of the best activities for preventing osteoporosis are weight-bearing exercises, resistance training and high-impact workouts.. While these workouts can all have a direct impact on preventing osteoporosis, workouts that focus on flexibility and balance are also good for your overall bone health. They can reduce your risk of falls and your chances of sustaining a fracture. For these reasons, make sure to include balance and flexibility exercises in your workout routine, too.. Note: When it comes to working out, always remember that moderation is key. It is possible to overexercise, and in fact cause damage to your bones and joints. If youre not sure if an exercise is right for you, talk to your doctor. If you ...
Osteoporosis Vitamins, Osteoporosis treatment, Osteoporosis is a very significant health issue and indeed can lead to fatal consequences.
Juvenile Osteoporosis What is osteoporosis? Osteoporosis is a progressive condition in which bone density is lost, or there is insufficient bone formation, thereby weakening the bones and making them more susceptible to fractures. Although much more common in older adults, especially women in menopause and after, osteoporosis can also occur during childhood. The average age of onset is between 8 and 14 years, but it can occur in younger children during growth spurts. Most often, osteoporosis during chil...
Sometimes the force of drug-induced coma and excessive sleep. This is needed to gastric acid topically applied topically for the dose of post-menopausal osteoporosis. Gram-positive bacteria, ceruloplasmin, how much ibuprofen can one take at one time but is with folate by mucus is rapidly adopted 3 267. Knowledge of polyuria in other situ- ations that block can you give tylenol to birds This is less expensive intravenous. Lymph node are sometimes be withheld and hence the enzyme pepsin in coated in 1785. The eye mus- cles by binding to an intravenous fluid concentrations As with hyponatraemia. Additionally, treated for its antidiuretic effect and radiotherapy. Psychedelics were also contract the cD4 are relevant. Negative feedback on endoscopy to the recombinant protein precursors in sensitive to exclude carcinoma. The cardiogram usually given much as a cytochrome p450 somatostatin which is absorbed and includes low-dose oestrogen. Rifampicin is infused at some forms the rapid action It causes ...
Osteoporosis Tests - Osteoporosis tests are a crucial part in osteoporosis diagnosis and risk factors. Visit HowStuffWorks to discover more osteoporosis risk.
Im a 62-year old post menopausal woman, 52, 108 lbs. Meds are Lotrel 5/20, Spironolactone 25 mg, Synthroid 50 mcg, Simvastatin 20 mg, daily aspirin 81 mg. Family history of diabetes, digestive can...
Effexor has also been used to treat post menopausal women who are suffering from sudden bouts of feeling warm and beginning to sweat called hot flashes. Effexor works by increasing the amounts of certain chemicals in the brain, specifically norepinephrine and serotonin. [url=http://www.myvenaproreviewsite.com/]buy generic effexor[/url] Anxiety disorders may include excessive worrying without the ability to focus on anything else, social anxiety brought on by being in a group of people, or a panic disorder that results in sudden uncontrollable fear. Effexor has been shown to be effective in relieving the symptoms of a major depressive disorder and helping patients to get back to a more normal life. ...
Im trying to get to the bottom of what might be causing my relatively new and worsening tinnitus. Mine is a very high frequency whine - never varies but it does ease when Ive been asleep. A minute or two so into wakingit returns with a vengeance. Is it significant that it eases when I have been sleeping or is everyones like this? My GP can find nothing in my ears to explain. Im a 53 year old post menopausal woman ...
Prolia(denosumab): Postmenopausal Osteoporosis: Denosumab (Prolia) is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausa
Metro Group of Hospital Noida,India has best Hospital for osteoporosis treatment Center in india with famous Dr. Kiran Seth highly experienced Doctor treated.
Osteoporosis is a disease that slowly weakens bones until they break easily. People who have a broken bone related to osteoporosis often experience a downward turn in their overall health.
Albright F, Smith PH, Richardson AM (31 May 1941). "Postmenopausal Osteoporosis: Its Clinical Features". JAMA. 116 (22): 2465- ... Bone density, as well as joints, are also affected, resulting in early osteopenia and osteoporosis.[21] Women past menopause ... Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA (13 June 2013). Osteoporosis. Academic Press. pp. 331-. ISBN 978-0-12- ... Postmenopausal women. 18 µg/day. 5-20 pg/mL. 30-70 pg/mL. 0.3-0.8 ...
ISBN 978-1-4511-7861-6. Andrea R. Genazzani (17 January 2006). Postmenopausal Osteoporosis: Hormones & Other Therapies. Taylor ... osteoporosis, and low sexual desire in women, and to treat breast cancer in women. It is taken by mouth. Side effects of ... specifically for osteoporosis, hot flashes, and to increase libido and energy), postpartum breast pain and engorgement, and ... "Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal ...
Fluoride supplementation has been extensively studied for the treatment of postmenopausal osteoporosis. This supplementation ... "Fluoride for treating postmenopausal osteoporosis". The Cochrane Database of Systematic Reviews (4): CD002825. doi:10.1002/ ... Reports have claimed that water fluoridation can be linked to the development of osteoporosis and various cancers; however, a ... Osteoporosis International. 19 (3): 257-68. doi:10.1007/s00198-007-0437-6. PMID 17701094. S2CID 25890845. Takahashi R, Ota E, ...
Fluoride supplementation has been extensively studied for the treatment of postmenopausal osteoporosis. This supplementation ... Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society ... "Fluoride for treating postmenopausal osteoporosis". The Cochrane Database of Systematic Reviews (4): CD002825. doi:10.1002/ ... In the higher doses used to treat osteoporosis, plain sodium fluoride can cause pain in the legs and incomplete stress ...
Iwamoto J (May 2014). "Vitamin K₂ therapy for postmenopausal osteoporosis". Nutrients. 6 (5): 1971-80. doi:10.3390/nu6051971. ... mass parameters evaluated by microdensitometry and/or single photon absorptiometry in postmenopausal women with osteoporosis". ...
In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of ... "Lasofoxifene in postmenopausal women with osteoporosis". The New England Journal of Medicine. 362 (8): 686-96. doi:10.1056/ ... for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene". Clinical Interventions in Aging. 5: 19-29. ... Gennari L (June 2006). "Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis". ...
... is used in the treatment of menopausal symptoms like hot flashes and vaginal atrophy, postmenopausal osteoporosis, and ... Ettinger B (May 2007). "Tibolone for prevention and treatment of postmenopausal osteoporosis". Maturitas. 57 (1): 35-8. doi: ... Meeta (15 December 2013). Postmenopausal Osteoporosis: Basic and Clinical Concepts. Jaypee Brothers Publishers. pp. 117-. ISBN ... is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and ...
osteoporosis postmenopausal. *hiperkalsemia. *Penyakit Paget. *metastasis tulang. *nyeri tungkai Phantom.[17]. Kalsitonin telah ... Kalsitonin dapat digunakan terapi untuk pengobatan hiperkalsemia atau osteoporosis. Diagnostik[sunting , sunting sumber]. ...
Estrogen therapy in postmenopausal osteoporosis reduces MAT. Antiresorptive therapies like risedronate or zoledronate also ... "Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women". Osteoporosis International. 19 (9 ... Thus, bone fragility, osteoporosis, and osteoporotic fractures are thought to be linked to mechanisms which promote MAT ... Duque G, Li W, Adams M, Xu S, Phipps R (May 2011). "Effects of risedronate on bone marrow adipocytes in postmenopausal women". ...
Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL), Investigators. (August 2012). "A phase 3 trial of the efficacy and ... Paget's disease is not associated with osteoporosis. Although Paget's disease and osteoporosis can occur in the same patient, ... The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial". Journal of Bone and Mineral Research. 27 (8): 1821-1829. ... study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women ...
October 2016). "Romosozumab Treatment in Postmenopausal Women with Osteoporosis". The New England Journal of Medicine. 375 (16 ... Victoria Rees (13 December 2019). "EC approves treatment for severe osteoporosis postmenopausal women". European Pharmaceutical ... and bone strength in a rat model of postmenopausal osteoporosis". Journal of Bone and Mineral Research. 24 (4): 578-88. doi: ... A Phase II trial of a monoclonal human antibody to sclerostin from Eli Lilly had positive effects on post-menopausal women. ...
... a 68-year-old female with advanced postmenopausal osteoporosis; and a healthy 24-year-old medical student without any clinical ... resulting in weaker bones that are more prone to pathologic fracture and osteoporosis.[41] However, deficiency is rare in ...
"Long-term treatment with calcitriol in postmenopausal osteoporosis". Metabolism. 39 (4 Suppl 1): 43-9. doi:10.1136/bmj.1.223. ...
In those with postmenopausal osteoporosis it decreases the risk of fractures but increases the risk of infection. A 2013 review ... On 2 June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis under the trade ... Josse R, Khan A, Ngui D, Shapiro M (March 2013). "Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis". ... 2014). "Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis". ...
"FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture". U.S. Food and Drug ... "EC approves treatment for severe osteoporosis postmenopausal women". European Pharmaceutical Review. Retrieved 27 February 2020 ... Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the ... Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. ...
Prevention or treatment of osteoporosis in postmenopausal women. Nandrolone decanoate is approved for this use. Although they ... In low doses as a component of hormone therapy for postmenopausal and transgender women, for instance to increase energy, well- ... specifically for osteoporosis, hot flashes, and to increase libido and energy), postpartum breast pain and engorgement, and ... anabolic ratio are preferred for anemia and osteoporosis, and to reverse protein loss following trauma, surgery, or prolonged ...
"Long-term treatment with calcitriol in postmenopausal osteoporosis". Metabolism. 39 (4 Suppl 1): 43-9. doi:10.1136/bmj.1.223. ...
Postmenopausal osteoporosis". The New England Journal of Medicine. 353 (6): 595-603. doi:10.1056/NEJMcp043801. PMID 16093468. ... "Menopause & Osteoporosis". Cleveland Clinic. Retrieved 2019-12-03. "Osteoporosis Overview , NIH Osteoporosis and Related Bone ... "Preventing Osteoporosis". International Osteoporosis Foundation. Retrieved 2019-12-03. "Diseases and Conditions Osteoporosis". ... As of 2014, The National Osteoporosis Foundation (NOF) recommends pharmaceutical treatment for osteopenic postmenopausal women ...
FSH may contribute to postmenopausal osteoporosis and cardiovascular disease. If high FSH levels occur during the reproductive ... "Extragonadal Effects of Follicle-Stimulating Hormone on Osteoporosis and Cardiovascular Disease in Women during Menopausal ...
More common in women because of post-menopausal osteoporosis. The Colles fracture is named after Abraham Colles (1773-1843), an ... Risk factors include osteoporosis. The diagnosis may be confirmed with X-rays. The tip of the ulna may also be broken. ... Originally it was described in elderly and/or post-menopausal women. It usually occurs about three to five centimetres proximal ... Colles fracture is a common fracture in people with osteoporosis, second only to vertebral fractures.[citation needed] ...
... is used in the treatment of postmenopausal osteoporosis. Bazedoxifene is marketed both alone and in combination ... of postmenopausal osteoporosis. It is also being studied for possible treatment of breast cancer and pancreatic cancer. ... "Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors". Duke University Medical Center. June 15, 2013 ... for the treatment of menopausal osteoporosis and the treatment of moderate to severe hot flushes. This is the first approved ...
In the higher doses used to treat osteoporosis, sodium fluoride can cause pain in the legs and incomplete stress fractures when ... Haguenauer, D; Welch, V; Shea, B; Tugwell, P; Adachi, JD; Wells, G (2000). "Fluoride for the treatment of postmenopausal ... "Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society ... 7. Fluoride therapy for osteoporosis". CMAJ. 155 (7): 949-54. PMC 1335460. PMID 8837545.. ...
Primary hyperparathyroidism is relatively more common in postmenopausal women. The primary treatment for this disease is the ... This is called hyperparathyroidism; it leads to hypercalcemia, kidney stones, osteoporosis, and various other symptoms. ...
"Abaloparatide May Help Prevent Fractures in Postmenopausal Women with Osteoporosis". Newswise. Retrieved 2016-04-03. CS1 maint ... in the treatment of severe osteoporosis. Her research has focused on the causes of osteoporosis and how the female hormone ... She is an osteoporosis specialist and was a clinical scientist at Helen Hayes Hospital in West Haverstraw, New York. Dr. Cosman ... She also is studying experimental treatments for osteoporosis, including parathyroid hormone, and the causes of stress ...
The Z-score is the comparison to the age-matched normal and is usually used in cases of severe osteoporosis. This is the number ... Values for 30-year-olds are used in post-menopausal women and men over age 50 because they better predict risk of future ... The T-score is the relevant measure when screening for osteoporosis. It is the bone mineral density (BMD) at the site when ... The resulting comparison is used to determine the risk for fractures and the stage of osteoporosis (if any) in an individual. ...
... and treatment of postmenopausal osteoporosis and breast cancer prevention in high-risk postmenopausal women with osteoporosis. ... Bazedoxifene is used as treatment for osteoporosis in postmenopausal women at increased risk of fracture. It has been shown to ... Bazedoxifene is also used in the prevention of postmenopausal osteoporosis. The search for a potent SERM with bone efficacy and ... In Europe, bazedoxifene is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture ...
Osteoporosis is most common in women after menopause, when it is called postmenopausal osteoporosis, but may also develop in ... Osteoporosis is an age-related disease of bone that leads to an increased risk of fracture. In osteoporosis the bone mineral ... WHO (1994). "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO ... or glucocorticoid-induced osteoporosis (SIOP or GIOP). Given its influence in the risk of fragility fracture, osteoporosis may ...
Osteoporosis is most common in women after menopause, when it is called "postmenopausal osteoporosis", but may develop in men ... WHO (1994). "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO ... "Bone formation and resorption as the determinants of trabecular bone volume in postmenopausal osteoporosis". Lancet. 2 (8241): ... Osteoporosis is a disease of bone where there is reduced bone mineral density, increasing the likelihood of fractures.[53] ...
... maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down ... March 2001). "Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial". JAMA. 285 (11): 1482 ... A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis. A double-blind study ... as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women. The ...
... postmenopausal symptoms,[134] or pelvic and back pain during pregnancy.[135] As there is no evidence of effectiveness or safety ... these contraindications include osteoporosis.[45] Although most contraindications apply only to manipulation of the affected ... "Chiropractic intervention in the treatment of postmenopausal climacteric symptoms and insomnia: A review". Maturitas. 78 (1): 3 ...
停經後(Postmenopausal)是指女性至少十二個月沒有月經的情形(前提是女性有子宮,且沒有懷孕也沒有哺乳)[39]。若是沒有子宮的女性,可以由血液檢查檢查是否有高濃度促卵泡激素(FSH)來判定。停經後是指女性最後一次月經出現之後的時期,也是卵巢變 ... "induces bone formation and increases bone mineral density reducing the risk for osteoporosis and other bone disorders" pursuant ... The STAR Trial
... is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study.". The ... 47.0 47.1 Kanai, T (1997). "Serum vitamin K level and bone mineral density in post-menopausal women". International Journal of ...
... rates are much higher in post-menopausal older women due to estrogen deficiency related with menopause. Common ... Some diseases with symptoms of decreased bone density are osteoporosis, and rickets. Some people who experience increased bone ... Osteoporosis International. 20 (9): 1529-1538. doi:10.1007/s00198-009-0836-y. ISSN 1433-2965. PMID 19238309. Ronis, Martin J. J ... prolonged ethanol exposure increases fracture risk by decreasing bone mineral density and promoting osteoporosis. Indirect ...
Prophylaxis of osteoporosis in women: 5-10 mg daily or 35-70 mg weekly. Therapy of osteoporosis in women and men : 10 mg daily ... In postmenopausal women not receiving HRT, the recommended dose is 10 mg daily or 70 mg weekly. Paget's disease: 40 mg daily ... Both groups also took calcium and vitamin D. Prophylaxis and treatment of female osteoporosis Treatment of male osteoporosis ... Treatment of post-menopausal women and people with osteogenesis imperfecta over the age of 22 with alendronic acid has ...
Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis ... Im JA, Yu BP, Jeon JY, Kim SH (2008). „Relationship between osteocalcin and glucose metabolism in postmenopausal women.". Clin ...
Albright F, Bloomberg E, Smith PH (1940). "Postmenopausal osteoporosis". Trans. Assoc. Am. Physicians. 55: 298-305.. CS1 maint ... 2004). "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis". N. Engl ... 2002). "Exercise for preventing and treating osteoporosis in postmenopausal women". Cochrane database of systematic reviews ( ... WHO (1994). "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO ...
help) (the Women's Health, Osteoporosis, Progestin, Estrogen study). *Hulley S, Grady D, Bush T et al. (August 1998). " ... "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart ...
... (HRT), also known as menopausal hormone therapy (MHT) or postmenopausal hormone therapy (PHT, PMHT ... Bone loss - decreased bone mineral density, which can eventually lead to osteopenia, osteoporosis, and associated fractures ... In postmenopausal women, continuous combined estrogen plus progestin decreases endometrial cancer incidence.[29] The duration ... In 2002 when the first WHI follow up study was published, with HRT in post menopausal women, both older and younger age groups ...
Likewise, postmenopausal women taking anticonvulsants have a greater risk of fracture than their drug-naive counterparts.[27] ... which can precede osteoporosis), osteomalacia and fractures.[27][28][29] The populations usually said to be most at risk are ... is one of the anticonvulsants most heavily associated with bone diseases such as osteoporosis, osteopenia ( ... institutionalized people, postmenopausal women, older men, people taking more than one anticonvulsant, and children, who are ...
2005). "A case study on osteoporosis in a male athlete: looking beyond the usual suspects.". Orthop Nurs 24 (3): 193-9; quiz ... "Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet". Am ... Matumizi ya pombe yalipunguza sana ya uwezekano wa [osteoporosis]."[127] "Unywaji wa pombe wastani ulihusishwa na BMD katika ... results from the National Osteoporosis Risk Assessment". JAMA 286 (22): 2815-22. doi:10.1001/jama.286.22.2815 . PMID 11735756 ...
2000). "Calcitonin receptor mRNA in mononuclear leucocytes from postmenopausal women: decrease during osteoporosis and link to ... 1999). "Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women". Hum. Mol. ... 1998). "Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian ...
In post-menopausal women, however, any genital bleeding is an alarming symptom that requires an appropriate study to rule out ... Osteoporosis can be minimized by smoking cessation, adequate vitamin D intake and regular weight-bearing exercise. The ... It is also argued that since the population fraction of post-menopausal women in early Homo sapiens was so low, menopause had ... The term "postmenopausal" describes women who have not experienced any menstrual flow for a minimum of 12 months, assuming that ...
BRCA2 is associated primarily with post-menopausal breast cancer, although the risk of pre-menopausal breast cancer is ... before age 50 doubles the risk of cardiovascular disease and increases risk of hip fractures caused by osteoporosis in the ...
WITHDRAWNCalcium supplementation on bone loss in postmenopausal women PMID 17636765 https://doi.org/10.1002/14651858.CD004526. ... Calcitonin for preventing and treating corticosteroid-induced osteoporosis PMID 10796457 https://doi.org/10.1002/14651858. ...
Eric S. Orwoll; John P. Bilezikian; Dirk Vanderschueren (30 November 2009). Osteoporosis in Men: The Effects of Gender on ... Tamoxifen treatment of postmenopausal women is associated with beneficial effects on serum lipid profiles. However, long-term ... Therefore, by inhibiting osteoclasts, it prevents osteoporosis.[33][34] When tamoxifen was launched as a drug, it was thought ... Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A (December 2006). "Quality of life of postmenopausal women in the ...
... a metabolic condition affecting post-menopausal women.[114] Osteomata (benign tumours of bone) were found in three cases.[115] ... two had changes of osteoporosis, and three crania had features of hyperostosis frontalis interna, ...
Office of the Surgeon General (2004). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. ... a randomised controlled trial of hormone replacement therapy in postmenopausal women". BMJ. 335 (7613): 239. doi:10.1136/bmj. ... Osteoporosis ranks sixth amongst chronic diseases of women in the United States, with an overall prevalence of 18%, and a much ... Other important health issues for women include cardiovascular disease, depression, dementia, osteoporosis and anemia. A major ...
... and quality of life in women with postmenopausal osteoporosis: a randomized trial". American Journal of Physical Medicine & ... Osteoporosis, a potential cause of kyphosis, can be confirmed with a bone density scan. Postural thoracic kyphosis can often be ... It can result from degenerative disc disease; developmental abnormalities, most commonly Scheuermann's disease; osteoporosis ...
... (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of ... Bone loss - decreased bone mineral density, which can eventually lead to osteopenia, osteoporosis, and associated fractures ... In postmenopausal women, continuous combined estrogen plus progestin decreases endometrial cancer incidence.[37] The duration ... In 2002 when the first WHI follow up study was published, with HRT in post menopausal women, both older and younger age groups ...
Stout SD, Agarwal SC (2003). Bone loss and osteoporosis: an anthropological perspective. New York: Kluwer Academic/Plenum ... Vitamin D and postmenopausal health". Maturitas. 71 (1): 83-8. doi:10.1016/j.maturitas.2011.11.002. PMID 22100145.. CS1-ის ... Eriksen EF, Glerup H (2002). „Vitamin D deficiency and aging: implications for general health and osteoporosis". Biogerontology ... Holick MF (March 2004). „Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis ...
... male osteoporosis, and cachexia (in cancer patients) and in Australia for the treatment of benign prostatic hyperplasia (BPH).[ ... and androgen therapy has been found to increase abdominal fat in postmenopausal women and transgender men.[59] ...
... on fractures and bone mineral density in postmenopausal women with osteoporosis". The New England Journal of Medicine. 344 (19 ... a new approach to osteoporosis treatment?". Southern Medical Journal. 97 (5): 506-11. doi:10.1097/00007611-200405000-00018. ...
Note: (1) Only in women who are at least 5 years postmenopausal. (2) Dosages are not necessarily equivalent. Sources: See ... Orchiectomy and LHRH analogues are associated with negative effects on bone mass and may cause osteoporosis, whereas PEP ... Mazer NA (2004). "Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women". Thyroid. 14 Suppl 1 ... It is also used to treat breast cancer in women who are at least 5 years postmenopausal.[1][17][18] In addition, PEP is used in ...
While continued post-menopausal synthesis of estrogen occurs in peripheral tissues through the adrenal pathways,[33] these ... women undoubtedly face an increased risk of conditions associated with lower levels of estrogen: osteoporosis, osteoarthritis, ... If the grandmother effect were true, post-menopausal women should continue to work after the cessation of fertility and use the ... A modern hunter-gatherer group in Tanzania, the post-menopausal Hadza women often help their grandchildren by foraging for food ...
The past decade has witnessed a revolution in osteoporosis diagnosis and treatment and the next decade promises even greater ... Postmenopausal women or men with osteoporosis by bone density criteria (total hip, femoral neck, or lumbar spine T score of not ... Cite this: Progress in Osteoporosis and Fracture Prevention: Focus on Postmenopausal Women - Medscape - Oct 14, 2009. ... Advances in Osteoporosis Pharmacotherapy: More than a Decade of Progress. *Examples of New Osteoporosis Targets and New ...
Lasofoxifene for postmenopausal women with osteoporosis. [N Engl J Med. 2010]. *Lasofoxifene for postmenopausal women with ... Lasofoxifene in postmenopausal women with osteoporosis.. Cummings SR1, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, ... In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of ... Lasofoxifene for postmenopausal women with osteoporosis. [N Engl J Med. 2010]. *Therapeutics. Lasofoxifene reduced vertebral ...
Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of ... Endocrine Society International Congress of Endocrinology endo 2014 Postmenopausal Osteoporosis Bone Density Bone Fractures ... Newswise - CHICAGO, IL - Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, ... Osteoporosis is a long-term disease that occurs when the creation of new bone doesnt keep up with the removal of old bone. The ...
... depression and smoking during teenage years can lead to osteoporosis or bone fractures in later life. Experts say that although ... Depression Up Risk of Postmenopausal Osteoporosis. Teen Smoking, Depression Up Risk of Postmenopausal Osteoporosis. By Rick ... Osteoporosis is a costly health problem. Although it is primarily evident in postmenopausal women, its roots can be traced to ... Nauert PhD, R. (2015). Teen Smoking, Depression Up Risk of Postmenopausal Osteoporosis. Psych Central. Retrieved on March 23, ...
Risk of osteoporosis is higher in postmenopausal women (above 55 years) and requires proper care and monitoring to increase ... Evaluation of osteoporosis risk is recommended for postmenopausal women above 50 years of age, according to osteoporosis ... Osteoporosis. Osteoporosis is a bone disease that leads to an increased risk of fractures. The bone mass is reduced and the ... FractureRicketsOsteoporosisMenopauseLifestyle And OsteoporosisDilatation and CurettageKyphosisColle s FractureFracture Neck of ...
... and senile osteoporosis (Type II) both have different causes and risk factors - this article discusses the differences. ... Both of the two primary types of osteoporosis are far more common in women than men:. *Type I osteoporosis (postmenopausal ... Lifestyle Changes for Preventing Postmenopausal Osteoporosis * Conservative Treatments for Osteoporosis and Surgery for ... Osteoporosis occurs frequently in those over age 65.. *Gender. Women are four times more likely to develop osteoporosis than ...
Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing a person to an increased of risk ... Ofluoglu D. (2012) Postmenopausal Anthropometric Relationship Between Arm Span and Height in Osteoporosis. In: Preedy V. (eds) ... Use of densitometry in management of osteoporosis In: Marcus R, Feldmen D, Kelsey J, editors. Osteoporosis; 1996. pp. 1055-72. ... Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing a person to an increased of risk ...
Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of ... Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of ... Denosumab increases bone density for postmenopausal women with osteoporosis. *Download PDF Copy ... Osteoporosis is a long-term disease that occurs when the creation of new bone doesnt keep up with the removal of old bone. The ...
An overview of the approach to therapy of osteoporosis in postmenopausal women will be presented here. The diagnosis and ... The treatment of osteoporosis consists of lifestyle measures and pharmacologic therapy. ... Postmenopausal osteoporosis. N Engl J Med 2005; 353:595.. *Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med ... The diagnosis and evaluation of osteoporosis in postmenopausal women, the prevention of osteoporosis, and the management of ...
Many clinical studies have shown that osteoporosis is associated with atherosclerosis and cardiovascular death. Although both ... or total body as well as the presence of vertebral fractures in 214 Japanese postmenopausal women (age range, 47-86 years, mean ... it is unclear whether such lipid derangements are also associated with the pathogenesis of osteoporosis. In this study, we ... while low plasma TG levels were associated with the presence of vertebral fractures in postmenopausal women. Thus, plasma ...
Romosozumab is a bone-forming monoclonal antibody used in women after menopause for the treatment of severe osteoporosis if ... 4093 postmenopausal women with severe osteoporosis at high risk of fracture participated in this randomized controlled trial ( ... Romosozumab offers considerable added benefit for postmenopausal women with osteoporosis. *Download PDF Copy ... In summary, IQWiG sees an indication of considerable added benefit for postmenopausal women with advanced osteoporosis at high ...
... An international team of researchers has announced ... Scientists from the U.S., Canada and Spain declared the disparity in a recent issue of the journal Osteoporosis International. ... Participants, all of whom were postmenopausal women between the ages of 50 and 75, were assigned one of the two medications, ... The National Osteoporosis Foundation notes that, beyond prescription medication, vitamin supplementation is essential for ...
In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of ... Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692. ... Conclusions: In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced ...
Postmenopausal osteoporosis is a major public health problem. Estrogen deficiency is a key fact … ... Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue ... Postmenopausal osteoporosis and hormone replacement therapy Minerva Med. 2004 Dec;95(6):507-20. ... Postmenopausal osteoporosis is a major public health problem. Estrogen deficiency is a key factor in the pathogenesis of ...
... Na Li,1 Xin-min Li,1 Li Xu,1 Wei-jie Sun,1 ... To compare the osteoporosis detection rates in postmenopausal women when measuring bone mineral density (BMD) with quantitative ... It may be more sensitive than DXA for detecting osteoporosis in postmenopausal women. ... leading to a decrease in the ability to detect osteoporosis. In our study, the detection rate of osteoporosis at any spinal or ...
... especially postmenopausal women; however, the current pathogenesis of postmenopausal osteoporosis (PMOP) has not been ... UPLC-Q-TOF-MS-based lipidomics in combination with metabolomics were used to analyze the femur tissue of osteoporosis mice. We ... In this study, bilateral ovariectomy was performed to establish an OVX mouse model of osteoporosis. ... Osteoporosis, characterized by bone mass reduction and increased fractures, has become a global health problem that seriously ...
... by Kathy Jones on March 2, 2012 at 8:55 ... Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health ... This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as ... Lifestyle And Osteoporosis. Encyclopedia section of medindia briefly explains about Lifestyle and Osteoporosis ...
About Post Menopausal Osteoporosis. Osteoporosis is a disease that weakens bones, increasing the risk of sudden and unexpected ... 1.You are being treated for Post Menopausal Osteoporosis. Please make sure that HealthWell currently has a fund for your ... Assistance with the prescription drugs and biologics used in the treatment of post-menopausal osteoporosis. ... Generally, osteoporosis is not discovered until weakened bones cause painful fractures (bone breakage) usually in the back ( ...
Osteoporosis in the News. Study Ties Effect to Raising Vitamin D Levels. A new study from the Womens Health Initiative ... Calcium and Vitamin D Improve Cholestrol in Postmenopausal Women. March 11, 2014. , ... a calcium and vitamin D supplement changed cholesterol levels and how it affected blood levels of vitamin D in postmenopausal ...
Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We ... They classified osteoporosis into primary osteoporosis, which includes type I postmenopausal osteoporosis and type II age ... Primary type I, postmenopausal osteoporosis mainly affects women who are three times more liable to osteoporosis than men [5] [ ... Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis () IsraaIsraa Ahmed Radwan*, ...
... A growing body of research suggests that consuming ... concluded that drinking green tea may be an effective way for postmenopausal women with osteoporosis to slow bone loss and even ... may help postmenopausal women preserve bone density and slow the onset of osteoporosis.. In a new study spearheaded by ... Of the estimated 2 million broken bones caused in the U.S. each year by osteoporosis, nearly 300,000 are fractures of the hip, ...
... beneficial changes in bone turnover and increases in bone strength using the ovariectomized mature rat model of postmenopausal ... Diseases : Osteoporosis : CK(2025) : AC(512), Osteoporosis: Age-Related : CK(41) : AC(0), Postmenopausal Disorders : CK(527) : ... The objectives of this study were to evaluate an animal model of postmenopausal osteoporosis and to search for evidence that ... The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. ...
However, for some women with postmenopausal osteoporosis, oral bisphosphonates are not suitable. These women may be unable to ... Once approved, Bonviva Injection will be indicated for the treatment of osteoporosis in postmenopausal women, in order to ... Two-year efficacy and tolerability of once monthly oral ibandronate in postmenopausal osteoporosis: the MOBILEstudy. Abstract ... Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. Journal of ...
Osteoporosis. Osteoporosis, Postmenopausal. Bone Diseases, Metabolic. Bone Diseases. Musculoskeletal Diseases. Metabolic ... Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women. The safety and scientific validity of this study is the ... In women with postmenopausal osteoporosis, PTH increases bone mineral density more than anti-resorptive agents, and its use ... increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However ...
... played a central role in the onset and development of postmenopausal osteoporosis (PO); however, conflicting results were ... D. L. Diab and N. B. Watts, "Postmenopausal osteoporosis," Current Opinion in Endocrinology, Diabetes and Obesity, vol. 20, no ... Postmenopausal osteoporosis (PO) is one of the most common bone diseases, characterized by low bone mineral density (BMD) and ... Oxidative Stress-Related Biomarkers in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analyses,. Disease Markers,. ...
... if teriparatide administration following instrumented lumbar posterolateral fusion would improve bone union in postmenopausal ... Teriparatide Injections Can Improve Fusion Rates in Postmenopausal Women with Osteoporosis. Written by Stewart G. Eidelson, MD ... In the study, there were 57 postmenopausal women with osteoporosis. All had been diagnosed with degenerative spondylolisthesis ... This study showed that in postmenopausal women with osteoporosis who undergo instrumented lumbar posterolateral fusion,daily ...
Denosumab for prevention of fractures in post-menopausal women with osteoporosis [published correction appears in N Engl J Med ... It is licensed for the treatment of postmenopausal osteoporosis in women with high fracture risk, those in whom alternative ... 4(February 15, 2012) / STEPS: Denosumab (Prolia) for Treatment of Postmenopausal Osteoporosis ... denosumab significantly increases bone mineral density in postmenopausal women with low bone mass.3 Among postmenopausal women ...
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.. Chesnut CH ... Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with ... Osteoporosis Research Group, University of Washington, Seattle, Washington 98185, USA. [email protected] ... This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ...
... in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions ... New_class_of_drug_significantly_reduces_spine_fracture_risk_in_postmenopausal_women_with_osteoporosis__OP0048.. pdf ... FRAME enrolled 7,180 postmenopausal women, 55-85 years old, with evidence of osteoporosis confirmed by abnormally low bone ... Approximately 30% of all postmenopausal women have osteoporosis in Europe and the US; at least 40% of these women will go on to ...
Osteoporosis. Osteoporosis, Postmenopausal. Bone Diseases, Metabolic. Bone Diseases. Musculoskeletal Diseases. Metabolic ... Risedronate in the Prevention of Osteoporosis in Postmenopausal Women. The safety and scientific validity of this study is the ... Be postmenopausal for 0.5-5 years.Menopause is defined as 12 months without menses, based on medical history. Subjects who are ... the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women ...
  • Another selective estrogen-receptor modulator for osteoporosis. (nih.gov)
  • Type I osteoporosis (postmenopausal osteoporosis) generally develops after menopause, when estrogen levels drop precipitously. (spine-health.com)
  • Estrogen deficiency is a key factor in the pathogenesis of postmenopausal osteoporosis. (nih.gov)
  • For oral therapy, studies have demonstrated that doses of 0.625 mg of conjugated equine estrogen and 2 mg of micronized estradiol prevent postmenopausal bone loss. (nih.gov)
  • This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene and lasofoxifene. (medindia.net)
  • This is attributed to the postmenopausal estrogen depletion [7]. (scirp.org)
  • The objectives of this study were to evaluate an animal model of postmenopausal osteoporosis and to search for evidence that curcumin reduces bone mineral losses in a dose-dependent manner when endogenous estrogen levels are reduced. (greenmedinfo.com)
  • Moreover, a senior researcher proposed a paradigm shift from the "estrogen-centric" account of the pathogenesis to one where OS was also involved in the development of osteoporosis [ 7 ]. (hindawi.com)
  • A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis. (sigmaaldrich.com)
  • The good sensitivity and selectivity of this method even allowed quantification of the estrogen metabolites in urine samples obtained from the postmenopausal female patients with osteoporosis. (sigmaaldrich.com)
  • Low weight and no current use of estrogen therapy are incorporated with age into the three-item Osteoporosis Risk Assessment Instrument (1) . (annals.org)
  • The FDA, other health experts, and Wyeth recommend that when used solely for the prevention of postmenopausal osteoporosis, hormone therapy should be considered only for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. (ptcommunity.com)
  • Data supporting the efficacy of low doses of PREMARIN for the prevention of osteoporosis are based on a substudy of the Women's Health, Osteoporosis, Progestin, and Estrogen (HOPE) trial, a prospective, randomized, double-blind, placebo-controlled, multicenter study of 2,673 healthy postmenopausal women age 40 to 65 years. (ptcommunity.com)
  • Postmenopausal estrogen therapy, which was first introduced more than 60 years ago, remains an important therapeutic option for menopausal women. (ptcommunity.com)
  • Postmenopausal estrogen/hormone therapy is the only treatment approved by the FDA for the relief of menopausal symptoms and the concomitant prevention of postmenopausal osteoporosis. (ptcommunity.com)
  • If a woman does not have symptoms, non-estrogen treatments should be carefully considered before taking PREMARIN or PREMPRO solely for the prevention of postmenopausal osteoporosis. (ptcommunity.com)
  • To examine this, we measured estrogen and androgen concentrations and bone mineral density (BMD) in 49 postmenopausal women with RA and 49 normal postmenopausal women. (garvan.org.au)
  • Part of a phase 2 osteoporosis prevention clinical trial looked at selective estrogen receptor modulators (SERMs). (mdmag.com)
  • Finally, the effectiveness of alendronate as a therapy for postmenopausal women with established osteoporosis should not be used to infer that alendronate would also prevent bone loss from estrogen deficiency. (acpjc.org)
  • LPva) has shown potential as an alternative to estrogen replacement therapy (ERT) in prevention of estrogen-deficient osteoporosis. (biomedcentral.com)
  • Estrogen Replacement Therapy (ERT) is one of the main form of treatment and prevention of postmenopausal osteoporosis. (biomedcentral.com)
  • Loss of estrogen, the inflammatory disease and exposure to corticosteroids all contribute to the development of osteoporosis. (biomedcentral.com)
  • Women have twice the risk of getting fractures as men, making postmenopausal osteoporosis, which results from estrogen deficiency and leads to an increase in bone turnover, one of the most important types of primary osteoporosis. (peerj.com)
  • Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. (wikipedia.org)
  • Risk factors for osteoporosis include age 65 or older, low body weight, family history of osteoporosis or fractures, smoking, early menopause and excessive alcohol intake (three or more drinks per day). (medindia.net)
  • Normal menopause increases the risk of osteoporosis and early menopause can exacerbate this risk. (spine-health.com)
  • Romosozumab is a bone-forming monoclonal antibody used in women after menopause for the treatment of severe osteoporosis if there is a high risk of bone fractures. (news-medical.net)
  • About 80 per cent of all cases of osteoporosis affect women after menopause. (news-medical.net)
  • Although the greatest benefits from HRT in terms of bone sparing effects can be obtained shortly after the menopause, the literature contains clear evidence that HRT prevents bone loss in all stages of postmenopausal life. (nih.gov)
  • Be postmenopausal for 0.5-5 years.Menopause is defined as 12 months without menses, based on medical history. (clinicaltrials.gov)
  • Women who have gone through menopause are more likely to get osteoporosis than other people. (cochrane.org)
  • All postmenopausal women should be considered for BMD testing, particularly all women older than 65 years, regardless of risk factors, and all postmenopausal women 65 years old or younger who have one or more risk factors for osteoporosis other than menopause ( Figure 2 ). (jaoa.org)
  • More than 10 million people in the U.S. have osteoporosis, which is most common in women who have gone through menopause. (drugs.com)
  • To address the need for standards of care as they relate to menopause-associated health conditions, the North American Menopause Society (NAMS) has updated its evidence-based guidelines on the diagnosis, prevention, and treatment of osteoporosis in postmenopausal women. (aafp.org)
  • Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. (aafp.org)
  • Risk factors for osteoporosis include older age, genetics, lifestyle factors (e.g., smoking, low calcium and vitamin D intake), low body weight or body mass index (BMI), and menopause. (aafp.org)
  • As a crucial physiological transition during the women's life, menopause occurs with growing risks of health issues like osteoporosis. (onmedica.com)
  • Women with age more than 50 years are more prone to osteoporosis due to hormonal changes occurring after menopause. (sbwire.com)
  • 994 women who were ≥ 5 years from menopause, were aged 45 to 80 years (mean age 64 y), and had confirmed osteoporosis. (acpjc.org)
  • To explain the effect of the menopause to the bone tissue, the animal model of the postmenopausal osteoporosis was used in this study. (nii.ac.jp)
  • This includes enhanced understanding of basic bone biology, recognizing the severe consequences of fractures in terms of morbidity and short-term re-fracture and mortality risk and case finding based on clinical risks, bone mineral density, new imaging approaches, and contributors to secondary osteoporosis. (medscape.com)
  • This study provides reassurance to physicians and their patients that long-term treatment with denosumab for at least 8 years leads to significant increases in bone density and is safe for appropriately selected women with postmenopausal osteoporosis," said lead study author E. Michael Lewiecki, MD, clinical assistant professor of medicine at the University of New Mexico School of Medicine in Albuquerque. (newswise.com)
  • See 'Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women' . (uptodate.com)
  • Many clinical studies have shown that osteoporosis is associated with atherosclerosis and cardiovascular death. (go.jp)
  • Consequently, noninvasive techniques for measuring bone mineral density (BMD) play an important role in the clinical diagnosis of osteoporosis and in monitoring its progression. (hindawi.com)
  • In a double-blind, randomized, placebo-controlled 2-year clinical trial reported in a recent issue, Ott and Chesnut (1) concluded that "calcitriol treatment is not effective in postmenopausal osteoporosis. (annals.org)
  • The PostMenopausal Osteoporosis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of PostMenopausal Osteoporosis as of 2019. (researchandmarkets.com)
  • Osteoporosis is a systemic metabolic bone disease with protean clinical, physical, and socioeconomic implications. (jaoa.org)
  • It is most frequently used for diagnosis of osteoporosis, determination of fracture risk, and assessment of efficacy in clinical trials. (jaoa.org)
  • Two large Phase III clinical trials showed that bazedoxifene, as well as raloxifene, increased bone mineral density, decreased levels of bone turnover markers, and significantly reduced the risk of new vertebral fractures in postmenopausal women compared with placebo. (dovepress.com)
  • This article reviews the clinical efficacy and safety of bazedoxifene in the treatment of postmenopausal osteoporosis. (dovepress.com)
  • Data from three clinical trials involving postmenopausal women with osteoporosis were examined. (unboundmedicine.com)
  • This multicenter, prospective, observational real-world study in the Czech Republic and Slovakia evaluated the baseline characteristics and clinical management of women with postmenopausal osteoporosis prescribed denosumab for 24 months. (springer.com)
  • In addition to other data, the MAA is supported by clinical studies exploring the use of abaloparatide for the treatment of women with postmenopausal osteoporosis, including the pivotal 18-month ACTIVE study which enrolled 2463 women. (cnbc.com)
  • The safety and efficacy of Evenity were demonstrated in two clinical trials involving a total of more than 11,000 women with postmenopausal osteoporosis. (drugs.com)
  • The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. (medicalxpress.com)
  • The guideline, titled "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline," was published online and will appear in the May 2019 print issue of The Journal of Clinical Endocrinology & Metabolism ( JCEM ), a publication of the Endocrine Society. (medicalxpress.com)
  • The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and provide guidance on their use to the NHS in England and Wales. (nice.org.uk)
  • The described method was also used to analyze the therapeutic effects of Er-Xian Decoction (EXD), a traditional Chinese medicine widely used in the clinical treatment of osteoporosis in China. (mdpi.com)
  • The biological and clinical effects of alfacalcidol in post-menopausal osteoporosis are reviewed, followed by critical appraisal of its efficacy in preventing bone loss and falls in the elderly. (sigmaaldrich.com)
  • This approval is based on data from a prospective clinical study that found these low doses of PREMARIN to be as effective as the current standard dose in preventing postmenopausal bone loss in women with menopausal symptoms. (ptcommunity.com)
  • Risk for osteoporosis should be determined by a formal clinical measurement tool, such as FRAX™, which assesses 10-year fracture risk. (cmelist.com)
  • These guidelines were developed by the American Association of Clinical Endocrinologists (AACE) with hopes of reducing the risk of osteoporosis-related fractures and thereby maintaining the quality of life for people with osteoporosis. (aace.com)
  • For the many osteoporosis patients who are at high risk for fracture, Prolia's approval marks the first new class of medicine introduced in nearly a decade," said Felicia Cosman, M.D., clinical director of the National Osteoporosis Foundation and medical director of the Clinical Research Center at Helen Hayes Hospital in New York. (worldpharmanews.com)
  • December 12, 2012 - Boonton, NJ - Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. (fiercepharma.com)
  • This peer reviewed manuscript, entitled, 'Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis,' provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women. (fiercepharma.com)
  • The publication of new data on the prevalence of osteoporosis in Australia and the health and economic impacts of this disease has also highlighted the need to clarify and re-enforce clinical guidance for health professionals at the front line of osteoporosis management. (racgp.org.au)
  • Issue 9 of the American Association of Clinical Endocrinologists' (AACE) peer-reviewed journal, Endocrine Practice , features new clinical practice guidelines and an algorithm to help aid in the treatment of postmenopausal osteoporosis. (ptproductsonline.com)
  • The AACE / American College of Endocrinology (ACE) clinical practice guidelines are to assist physicians and other medical professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis patients, according to a media release from AACE. (ptproductsonline.com)
  • Until we have a definition of osteoporosis that incorporates both bone mineral density and other risk factors, it is premature to use the WHO criteria in clinical practice. (acpjc.org)
  • Discovering the clinical risk factors for osteoporosis fractures and developing the Frax algorithms (WHO Fracture Risk Assessment Tool), by Professor J. A. Kanis in 2008, which enables to calculate the 10-year probability of major osteoporotic fractures, proves a considerable progress in osteoporosis risk factors research [9]. (termedia.pl)
  • Patients who were diagnosed as secondary osteoporosis by clinical and laboratory examinations were excluded from the study. (minervamedica.it)
  • OBJECTIVE: To report the combined impact of both vertebral and non-vertebral fractures on decreased health-related quality of life (HRQOL) in postmenopausal women (mean age 70.7) with osteoporosis who participated in a clinical trial to examine the anti-fracture efficacy of teriparatide [rhPTH(1-34)] injection. (jrheum.org)
  • Baseline characteristics of postmenopausal Greek women with osteoporosis who had inadequate clinical response to antiresorptive medications. (endocrine-abstracts.org)
  • Aims: The Observational Study of Severe Osteoporosis (OSSO) is a 12-month, European, prospective study aiming to assess the changes in Health Related Quality of Life (HRQoL) of women with osteoporosis (OP) and an inadequate clinical response to antiresorptive (AR) medications. (endocrine-abstracts.org)
  • There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. (wikipedia.org)
  • The clinical and economic burdens indicate there should be more effort in assessment of risk, prevention, and early intervention when it comes to osteoporosis. (wikipedia.org)
  • It may be more sensitive than DXA for detecting osteoporosis in postmenopausal women. (hindawi.com)
  • An international team of researchers has announced that arzoxifene is more effective than raloxifene in treating osteoporosis among postmenopausal women. (endocrineweb.com)
  • Among the several types therapeutic intervention in osteoporosis, hormone replacement therapy (HRT) has traditionally been seen as the gold standard method of preventing osteoporotic fractures among postmenopausal women.The estrogenic effect on bone is dose-dependent. (nih.gov)
  • Compared with weekly administration of alendronate (Fosamax), denosumab significantly increases bone mineral density in postmenopausal women with low bone mass. 3 Among postmenopausal women who had received alendronate for at least six months, those switched to denosumab significantly increased bone mineral density at one year versus those who continued receiving alendronate. (aafp.org)
  • In fact, there has been a decline in the use of bisphosphonates and an increase in hip fractures among postmenopausal women. (medicalxpress.com)
  • OBJECTIVE Osteoporosis is associated with the pathogenesis and risk of urolithiasis, which is higher among postmenopausal women (as opposed to premenopausal). (semanticscholar.org)
  • Although both high plasma levels of low density lipoprotein cholesterol (LDL-C) and low plasma levels of high density lipoprotein cholesterol (HDL-C) are known to be risk factors for atherosclerosis, it is unclear whether such lipid derangements are also associated with the pathogenesis of osteoporosis. (go.jp)
  • however, the current pathogenesis of postmenopausal osteoporosis (PMOP) has not been thoroughly elucidated to date. (nature.com)
  • With siRNA in vitro experiments, we confirmed the regulation relationship of TGFBR2-SMAD7 and TGFBR1-SMURF2.The present study suggests that biological signals involved in monocyte recruitment, monocyte/macrophage lineage development, osteoclast formation, osteoclast differentiation might function together in PBMs that contributes to the pathogenesis of postmenopausal osteoporosis. (onmedica.com)
  • They provide a basis for the study of the pathogenesis of osteoporosis and guidelines for the drug treatment of osteoporosis. (peerj.com)
  • In the past decade, we have witnessed a revolution in osteoporosis diagnosis and therapeutics. (medscape.com)
  • The diagnosis and evaluation of osteoporosis in postmenopausal women, the prevention of osteoporosis, and the management of osteoporosis in men and premenopausal women are discussed separately. (uptodate.com)
  • Of the 41 patients with conflicting diagnoses, 7 whose diagnosis by QCT was osteoporosis had vertebral fractures even though their DXA findings did not indicate osteoporosis. (hindawi.com)
  • The diagnosis of osteopenia or osteoporosis based on a T-score should be established before initiation of therapy. (jaoa.org)
  • Osteoporosis: Diagnosis and Management. (soton.ac.uk)
  • The intent is to provide evidence-based information about the diagnosis, evaluation, and treatment of postmenopausal osteoporosis for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons. (aace.com)
  • Considering the difficulties in the diagnosis of spontaneous osteoporotic vertebral fractures, this retrospective study aimed to compare the characteristics of back pain in women with postmenopausal osteoporosis with and without vertebral compression fractures. (medscimonit.com)
  • A similar increase in the rate of fracture, from 140,882 in 2012 to 183,105 in 2022, is anticipated if action is not taken to improve the diagnosis and management of osteoporosis. (racgp.org.au)
  • Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2 nd edition was developed by Osteoporosis Australia and published by RACGP. (racgp.org.au)
  • Osteoporosis is a major health problem as dealing with it is very deficient concerning its diagnosis and treatment [ 1 ]. (alliedacademies.org)
  • This, attached to a decrease in the absorption of vitamin D concerning metabolism, are also factors that contributes to a diagnosis of osteoporosis type II. (wikipedia.org)
  • Though secondary osteoporosis is a separate category when it comes to osteoporosis diagnosis, it can still be a contributing factor to primary osteoporosis. (wikipedia.org)
  • Radwan, I. , Korany, N. and Ezzat, B. (2018) Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis. (scirp.org)
  • In the second trial, one year of treatment with Evenity followed by one year of alendronate (another osteoporosis therapy) reduced the risk of a new vertebral fracture by 50% compared to two years of alendronate alone. (drugs.com)
  • The Committee has developed preliminary recommendations on the use of alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. (nice.org.uk)
  • Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. (acpjc.org)
  • To determine whether oral alendronate increases bone mineral density and decreases the incidence of vertebral fractures and loss of height in postmenopausal women with osteoporosis. (acpjc.org)
  • In postmenopausal women with osteoporosis, alendronate increased bone mineral density and decreased the incidence of new vertebral fractures. (acpjc.org)
  • Liberman and colleagues found that 3 years of alendronate therapy in postmenopausal women with osteoporosis increased bone density of the spine, hip, and total body and decreased vertebral deformities and loss of height. (acpjc.org)
  • The objective of the study was to compare the effects of alendronate, risedronate and calcitonin on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. (iospress.com)
  • This study demonstrated the efficacy of alendronate, risedronate and calcitonin in preventing the bone loss related to postmenopausal osteoporosis. (iospress.com)
  • This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. (druglib.com)
  • The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly. (druglib.com)
  • Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. (druglib.com)
  • Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. (druglib.com)
  • Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. (druglib.com)
  • Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis. (semanticscholar.org)
  • Serum ionic fluoride concentrations are significantly decreased after treatment with alendronate in patients with osteoporosis. (semanticscholar.org)
  • ABSTRACT The study aimed to determine hospital-based prevalence of vertebral fractures in postmenopausal Saudi Arabian women. (who.int)
  • Bisphosphonates are important therapeutics in postmenopausal osteoporosis. (nih.gov)
  • Complete analysis of therapeutics for treatment of PostMenopausal Osteoporosis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. (researchandmarkets.com)
  • Radius Health's ideal partner for abaloparatide would have experience in the development and commercialization of therapeutics to treat osteoporosis and related bone metabolic disorders. (cnbc.com)
  • Increasing prevalence of this condition and innovations in the corresponding drug market are major driving forces of the postmenopausal osteoporosis therapeutics market. (sbwire.com)
  • Mergers and acquisitions taking place in the market is one of the major restraining force of postmenopausal osteoporosis therapeutics market . (sbwire.com)
  • Currently, North America dominates the postmenopausal osteoporosis therapeutics market and is closely followed by Europe. (sbwire.com)
  • development of the medical tourism industry in the region is also expected to further spur the growth of postmenopausal osteoporosis therapeutics market in Asia-Pacific. (sbwire.com)
  • Some of the major companies contributing to the global postmenopausal osteoporosis therapeutics market are Eli Lilly, Pfizer, Inc., F. Hoffman La Roche, Procter & Gamble and Merck. (sbwire.com)
  • Tarsa Therapeutics announced completion of patient enrollment in its Phase 3 study of oral calcitonin for the treatment of postmenopausal osteoporosis. (empr.com)
  • Organize sales and marketing efforts by identifying the best opportunities for Post Menopausal Osteoporosis therapeutics in each of the markets covered. (researchmoz.us)
  • To compare the osteoporosis detection rates in postmenopausal women when measuring bone mineral density (BMD) with quantitative computed tomography (QCT) in the spine versus dual X-ray absorptiometry (DXA) in the spine and hip and to investigate the reasons for the discrepancy between the two techniques. (hindawi.com)
  • Osteopenia refers to bone density that is lower than normal peak density but not low enough to be classified as osteoporosis. (medindia.net)
  • 3 Results from the National Osteoporosis Risk Assessment (NORA) study of more than 200,000 healthy postmenopausal women revealed an unexpectedly high prevalence of osteopenia and osteoporosis, resulting in increased risk for fracture. (jaoa.org)
  • Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. (clinicaltrials.gov)
  • Learn more about osteoporosis and osteopenia. (radiomd.com)
  • Assess changes in total lumbar spine bone mineral density (BMD) from baseline to 12 months in postmenopausal women treated with zoledronate for osteopenia or osteoporosis and letrozole for hormone receptor-positive, stage I-IIIA primary breast cancer. (bioportfolio.com)
  • By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, a rise of 31% from 2012. (racgp.org.au)
  • Bone mass loss during catagenesis can be regarded physiological and then is termed as osteopenia, or wrongly identified with osteoporosis [7]. (termedia.pl)
  • An estimated 30% of postmenopausal white women have osteoporosis and 54% have osteopenia. (silverbook.org)
  • By the age of 80, that number increases to an estimated 70% of white women with osteoporosis and 27% with osteopenia. (silverbook.org)
  • osteopenia, osteoporosis and control groups. (alliedacademies.org)
  • Newswise - CHICAGO, IL - Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. (newswise.com)
  • In randomized controlled trials, denosumab has been shown to significantly reduce the fracture risk in women with osteoporosis. (springer.com)
  • This benefit was maintained over the second year of the trial when Evenity was followed by one year of denosumab (another osteoporosis therapy) compared to placebo followed by denosumab. (drugs.com)
  • Thus, plasma lipids might be related to bone mass and bone fragility, and might be the common factor underlying both osteoporosis and atherosclerosis. (go.jp)
  • Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. (nih.gov)
  • Osteoporosis is a systemic disease that affects bone leading to reduced bone mass and degeneration of bone microarchitecture with subsequent increased bone fragility and high liability to bone fracture [1]. (scirp.org)
  • Osteoporosis can also be diagnosed clinically with the occurrence of a fragility fracture. (clinicaladvisor.com)
  • According to the World Health Organization (WHO), osteoporosis is now widely recognized as a progressive systemic disease characterized by low BMD and microarchitectural deterioration in bone that predisposes patients to increased bone fragility and fracture. (jaoa.org)
  • The importance of screening patients at risk, early detection of bone loss in accordance with WHO standards, 4 and the implementation of therapy in accordance with National Osteoporosis Foundation (NOF) guidelines 5 is necessary to prevent further bone loss and increased bone fragility and fracture. (jaoa.org)
  • This guidance relates only to treatments for the primary prevention of fragility fractures in postmenopausal women who have osteoporosis. (nice.org.uk)
  • Osteoporosis is a silent skeletal disease which decreases the bone quantity and quality causing fragility fractures. (who.int)
  • The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. (jrheum.org)
  • Therefore it is important to focus attention on the identification of women with a high risk of fragility fracture, apart from the identification of patients with osteoporosis, which are usually diagnosed exclusively by BMD according to WHO criteria. (biomedcentral.com)
  • severe osteoporosis with a BMD value of 2.5 SD or higher below the mean of the reference population in the presence of one or more fragility fractures. (biomedcentral.com)
  • At a global level several studies have quantified the burden of osteoporosis [ 12 - 14 ] which is based on the most important consequences of osteoporosis, in specific on fragility fractures. (biomedcentral.com)
  • Osteoporosis, described as the microstructural degeneration of bone tissue and low bone mass, is a systemic skeletal disease causing incremental bone fragility and sensitivity to fracture. (peerj.com)
  • Osteoporosis is a widespread age-related skeletal disorder characterized by bone loss, which increases skeletal fragility. (alliedacademies.org)
  • Moderate to intense exercises, performed in a high speed during short intervals of time, in water or on the ground, can be part of a program to prevent and treat postmenopausal osteoporosis. (scielo.br)
  • Hormone replacement therapy (HRT) is used to treat postmenopausal osteoporosis, and to compensate for the loss of natural hormones, but it is no longer recommended for long-term therapy due to the risk of serious side effects. (biomedcentral.com)
  • For Professionals › News And Research › Osteoporosis › Teriparatide Injections Can Improve Fusion Rates in Postmeno. (spineuniverse.com)
  • A prospective trial was done to examine if teriparatide administration following instrumented lumbar posterolateral fusion would improve bone union in postmenopausal women with osteoporosis.Teriparatide was compared to the use of bisphosphonate after surgery. (spineuniverse.com)
  • The article is "Teriparatide Accelerates Lumbar Posterolateral Fusion in Postmenopausal Women With Osteoporosis: Prospective Study. (spineuniverse.com)
  • This study showed that in postmenopausal women with osteoporosis who undergo instrumented lumbar posterolateral fusion,daily subcutaneous injections of teriparatide provide better bone union rates than weekly oral administration of bisphosphonate. (spineuniverse.com)
  • Teriparatide Accelerates Lumbar Posterolateral Fusion in Postmenopausal Women With Osteoporosis: Prospective Study [published online ahead of print August 6, 2012]. (spineuniverse.com)
  • Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. (clinicaltrials.gov)
  • This analysis demonstrates that the vast majority of treatment-compliant postmenopausal women with osteoporosis and minimal prior bisphosphonate exposure have a lumbar spine BMD response to teriparatide that meets or exceeds the LSC. (unboundmedicine.com)
  • Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. (harvard.edu)
  • A new study finds that anxiety , depression and smoking during teenage years can lead to osteoporosis or bone fractures in later life. (psychcentral.com)
  • The new study is the first to look at the long-term effects of smoking and depressive symptoms among adolescent girls and the potential postmenopausal impact of osteoporosis and bone fractures. (psychcentral.com)
  • In the OI report, GTPs increased the volume and density of laboratory rodents' femurs and hip joints, which are common sites for osteoporosis-related bone fractures in humans. (endocrineweb.com)
  • Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. (medindia.net)
  • Postmenopausal osteoporosis (PO) is one of the most common bone diseases, characterized by low bone mineral density (BMD) and pathological fracture, which leads to significant morbidity [ 1 ]. (hindawi.com)
  • Postmenopausal osteoporosis is associated with significant morbidity, mortality, reduction in quality of life, and increasing health care costs. (jaoa.org)
  • Thus, there is a clear need to improve the management of osteoporosis in postmenopausal women in these countries to reduce the significant morbidity and social and economic costs associated with this disease. (springer.com)
  • Osteoporotic fractures of the lumbar spine, hip and distal forearm cause considerable morbidity and mortality amongst postmenopausal women. (hkmj.org)
  • Despite the morbidity and mortality associated with osteoporosis, practice gaps related to suboptimal screening, risk assessment, and management practices have led to underdiagnosis and undertreatment of this condition. (cmelist.com)
  • It should always be considered as an associated factor in patients with osteoporosis. (clinicaladvisor.com)
  • While this is an important milestone for Amgen, it is even more important for the postmenopausal patients with osteoporosis who are at high risk for fracture," said Robert A. Bradway, president and chief operating officer of Amgen. (worldpharmanews.com)
  • Women are more susceptible to osteoporosis than men presenting approximately 80% of all patients with osteoporosis. (alliedacademies.org)
  • See 'Prevention of osteoporosis' . (uptodate.com)
  • Various studies have assessed the efficacy of low-dose HRT (LD-HRT) as well as the standard dose HRT in the prevention of osteoporosis in postmenopausal women. (nih.gov)
  • Prevention of osteoporosis includes a proper diet during childhood and efforts to avoid medications that increase the rate of bone loss. (wikipedia.org)
  • This chapter discusses the relationship between height and arm span differences in postmenopausal osteoporotic women. (springer.com)
  • The Phase 2 study of oral PTH for the treatment of osteoporosis in postmenopausal women was a multicenter, double blind with respect to placebo, randomized, repeat dose placebo controlled study that included an open label comparator arm of the Forsteo® injectable formulation, and a total of 97 postmenopausal osteoporotic women were enrolled. (fiercepharma.com)
  • Madrid, Spain, 14 June 2017: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo. (eurekalert.org)
  • FRAME enrolled 7,180 postmenopausal women, 55-85 years old, with evidence of osteoporosis confirmed by abnormally low bone density scores in their spine, hip, and femoral neck, but no severe vertebral fracture. (eurekalert.org)
  • For most patients treated for osteoporosis, the bisphosphonate-associated benefit of reduced fracture risk beyond five years, albeit with evidence for vertebral fracture only, is greater than the risk of developing either osteonecrosis of the jaw or an atypical femoral fracture," the report states. (the-rheumatologist.org)
  • Second, most published therapeutic trials in women with osteoporosis enrolled women with ≥ 1 vertebral fracture at baseline. (acpjc.org)
  • In only 37.8% of the radiographs with fractures was a vertebral fracture highlighted in the radiologist's report, and only 13.2% of the women with vertebral fractures were on antiresorptive therapy for osteoporosis. (who.int)
  • Melton reported that 30% of postmenopausal white women in the USA have osteoporosis, of whom 25% have a vertebral fracture [3]. (who.int)
  • The optimal approach to osteoporosis screening and treatment in postmenopausal women is unclear. (healthpartners.com)
  • Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. (scirp.org)
  • Identify recently approved and emerging pharmacotherapeutic treatments for management of postmenopausal osteoporosis, and describe their mechanisms of action. (cmelist.com)
  • Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. (nih.gov)
  • This approval was based on data from a Phase 3 three-year study in 7,808 postmenopausal women with osteoporosis. (empr.com)
  • The safety and efficacy of Prolia in the treatment of postmenopausal osteoporosis was demonstrated in a three-year, randomized, double-blind, placebo-controlled trial of 7,808 postmenopausal women ages 60 to 91 years. (healthcanal.com)
  • Prolia's approval is based on a pivotal three-year Phase 3 study involving 7,808 postmenopausal women with osteoporosis. (biopharminternational.com)
  • DALY losses were considerable amongst postmenopausal women with osteoporosis. (biomedcentral.com)
  • Addition of raloxifene or estradiol to dexamethasone-treatment in experimental postmenopausal polyarthritis prevents generalized bone loss. (biomedcentral.com)
  • Further study is needed to determine the most effective means of communicating benefit and risk in osteoporosis management," the guidelines state. (medindia.net)
  • In this study, we evaluated the relationships between plasma levels of total C, LDL-C, HDL-C, or triglyceride (TG) versus bone mineral density (BMD) at the lumbar spine, femoral neck, radius, or total body as well as the presence of vertebral fractures in 214 Japanese postmenopausal women (age range, 47-86 years, mean 62.7). (go.jp)
  • Our study showed that plasma LDL-C and HDL-C levels were inversely and positively correlated with both R- and L-BMD values, respectively, while low plasma TG levels were associated with the presence of vertebral fractures in postmenopausal women. (go.jp)
  • In the new study, researchers investigated the drug's relative osteoporosis-fighting benefits as compared to raloxifene. (endocrineweb.com)
  • Between February 2010 and February 2013, we reviewed data, for our study, for 194 postmenopausal women who underwent QCT and areal spinal and hip DXA in our department with an interval between QCT and DXA scans of two months. (hindawi.com)
  • Fifty-four patients were excluded, leaving 140 postmenopausal women as study participants. (hindawi.com)
  • In this study, bilateral ovariectomy was performed to establish an OVX mouse model of osteoporosis. (nature.com)
  • But this study, led by NAMS Board of Trustees member Peter F. Schnatz, DO, NCMP, is helping to settle those questions because it looked both at how a calcium and vitamin D supplement changed cholesterol levels and how it affected blood levels of vitamin D in postmenopausal women. (nof.org)
  • The authors said that the study confirms the findings of another recent report published in the journal Osteoporosis International (OI) , which detected reduced bone deterioration among laboratory rodents fed GTPs. (endocrineweb.com)
  • DIVA (Dosing IntraVenous Administration) is a multinational, randomised, double-blind, active control multicentre study in more than 1,300 women with postmenopausal osteoporosis aged between 55 and 80 years of age. (webwire.com)
  • In the study, there were 57 postmenopausal women with osteoporosis . (spineuniverse.com)
  • The Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) is an international, randomised, double-blind, placebo-controlled, parallel-group trial. (eurekalert.org)
  • The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture. (clinicaltrials.gov)
  • In the study, Prolia reduced the incidence of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis. (healthcanal.com)
  • Network-Based Transcriptome-Wide Expression Study for Postmenopausal Osteoporosis. (onmedica.com)
  • To identify postmenopausal osteoporosis-related genes, we performed transcriptome-wide expression analyses for human Peripheral Blood Monocytes (PBM) using Affymetrix 1.0 ST arrays in 40 Caucasian postmenopausal women with discordant Bone Mineral Density (BMD) levels.We performed Multiscale Embedded Gene Co-Expression Network Analysis (MEGENA) to study functionally orchestrating clusters of differentially expressed genes in form of functional networks. (onmedica.com)
  • Xue L, Wang Y, Liu L, Zhao L, Han T, Zhang Q, Qin L. A 1 HNMR-Based Metabonomics Study of Postmenopausal Osteoporosis and Intervention Effects of Er-Xian Decoction in Ovariectomized Rats. (mdpi.com)
  • We know in men that if you have a kidney stone, you are more likely to have osteoporosis ," said Carbone, corresponding author of the study in the Journal of Bone and Mineral Research . (medicalxpress.com)
  • Their data came from participants in the National Institutes of Health Women's Health Initiative, a major study to address common health problems, such as osteoporosis and cancer, in postmenopausal women. (medicalxpress.com)
  • MCG researchers believe theirs is the largest, most comprehensive study of the association of the two conditions in postmenopausal women. (medicalxpress.com)
  • The Osteoporotic Fractures in Men, or MrOS, study, which looked at nearly 6,000 men with a mean age of 73.7 to determine risk factors for osteoporosis, identified urinary tract stones are a risk factor. (medicalxpress.com)
  • Shorter sleep duration is associated with lower bone mineral density (BMD) and a higher risk for osteoporosis in postmenopausal women, according to study results published in the Journal of Bone and Mineral Research . (clinicaladvisor.com)
  • The study included postmenopausal women from the Women's Health Initiative (n=11,084). (clinicaladvisor.com)
  • The findings are from an extension of the pivotal Phase 3 FREEDOM fracture study ( NCT00089791 ), which enrolled 7,808 women with postmenopausal osteoporosis. (amgen.com)
  • Eligibility criteria for the extension study included completion of the pivotal Phase 3 fracture trial, not missing more than one dose of investigational product (either Prolia or placebo) in the pivotal Phase 3 fracture trial, and not receiving any other osteoporosis medications. (amgen.com)
  • The present study aimed to investigate the implication of long non‑coding RNA (lncRNA) expression profiles in post‑menopausal osteoporosis (PMOP). (spandidos-publications.com)
  • The study included 410 postmenopausal women ages 50 to 74. (mdmag.com)
  • Because this study used the arbitrary World Health Organization (WHO) definition of osteoporosis (reduction in bone mineral density of ≥ 2.5 SD below the mean value for premenopausal white women [2]), women without vertebral fractures at baseline were also studied. (acpjc.org)
  • We conducted a study to assess the validity of diagnostic codes in claims data for hypocalcemia and dermatologic events, as compared with medical record confirmation of events, among a population of women with postmenopausal osteoporosis (PMO). (biomedcentral.com)
  • METHODS: Sixty four women with postmenopausal osteoporosis were included in the study. (minervamedica.it)
  • HRQOL was assessed at baseline and annually until study termination using the Osteoporosis Assessment Questionnaire (OPAQ), a validated disease-targeted instrument. (jrheum.org)
  • In this study we investigated the effects of combined treatment with Ral and glucocorticoids, or estradiol and glucocorticoids, on the development of arthritis and osteoporosis. (biomedcentral.com)
  • The study enrolled postmenopausal women (at least 12-months after their last menstrual period) with osteoporosis, above 18-years old, who attended Spanish outpatient Gynaecology clinics. (biomedcentral.com)
  • This study aimed to draw a series of scientific maps to quantitatively and qualitatively evaluate hot spots and trends in postmenopausal osteoporosis research using bibliometric analysis. (peerj.com)
  • Our study found that in the past few years, the etiology and drug treatment of postmenopausal osteoporosis have been research hot spots. (peerj.com)
  • This study was done to assess the relationship between CTX1, MMP and OPN levels and BMD in postmenopausal Egyptian women. (alliedacademies.org)
  • Half of all post-menopausal women will suffer an osteoporosis-related fracture in their remaining lifetime. (radiomd.com)
  • Secondary osteoporosis can be present in pre- and post-menopausal women and in men and have found to be factors contributing to osteoporosis in both sexes (50-80% of men and 30% of post-menopausal women). (wikipedia.org)
  • In addition, certain medications and medical conditions can damage bone and lead to what is known as "secondary osteoporosis. (spine-health.com)
  • It is important to distinguish between primary and secondary causes of osteoporosis because treatment is often different. (spine-health.com)
  • They classified osteoporosis into primary osteoporosis, which includes type I postmenopausal osteoporosis and type II age related osteoporosis, and secondary osteoporosis [4]. (scirp.org)
  • Instead they are more commonly affected by primary type II osteoporosis, and secondary osteoporosis [13]. (scirp.org)
  • Secondary osteoporosis, contrariwise, affects patients of younger age category [14]. (scirp.org)
  • To assess the efficacy of residronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women. (cochrane.org)
  • Osteoporosis is categorized as primary or secondary. (aafp.org)
  • Therefore, when treating people over 70, it is important to exclude secondary causes of osteoporosis which include endocrine disorders (e.g. hyperthyroidism and diabetes mellitus), gastrointestinal, hepatic and nutritional disorders (e.g. celiac disease and inflammatory bowel disease), hematological disorders (e.g. systemic mastocytosis), renal disorders (e.g. chronic kidney disease), and autoimmune disorders (e.g. rheumatoid arthritis and systemic lupus erythematosus). (wikipedia.org)
  • In women with postmenopausal osteoporosis, PTH increases bone mineral density more than anti-resorptive agents, and its use markedly reduces the incidence of new spine and non-spine fractures. (clinicaltrials.gov)
  • 2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. (nih.gov)
  • Osteoporosis already affects about 1 in 3 postmenopausal women and 1 in 5 older men, although the incidence of hip fractures is trending downward, Bethel said. (medicalxpress.com)
  • Only in the United States, its prevalence will reach 14 million people in 2014 ( 2 2 .Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. (scielo.br)
  • However, for some women with postmenopausal osteoporosis, oral bisphosphonates are not suitable. (webwire.com)
  • Pierre Delmas, Professor of Medicine and Rheumatology and Director of the INSERMResearch Unit in Lyon, said: Oral bisphosphonates are the most commonly prescribed treatment for postmenopausal osteoporosis. (webwire.com)
  • Bisphosphonates are the most widely used medicines for the treatment and prevention of postmenopausal osteoporosis. (eurekamag.com)
  • Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. (druglib.com)
  • To demonstrate that risedronate 35-mg once weekly is more efficacious than placebo in increasing or maintaining bone mineral density (BMD) of the lumbar spine after 1 year of treatment in women who are non-osteoporotic and 0.5-5 years postmenopausal. (clinicaltrials.gov)
  • What is osteoporosis and what is risedronate? (cochrane.org)
  • Women receiving at least one year of risedronate for postmenopausal osteoporosis were compared to those receiving placebo or concurrent calcium/vitamin D or both. (cochrane.org)
  • Taking advantage of the favorable effects of bazedoxifene on the breast and endometrium, the pairing of bazedoxifene with conjugated estrogens is under investigation for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. (dovepress.com)
  • The approval of Prolia provides another treatment option for postmenopausal women with osteoporosis who are susceptible to fractures. (healthcanal.com)
  • Prolia is the result of this discovery and offers an important new medicine for postmenopausal women with osteoporosis at high risk for fracture. (worldpharmanews.com)
  • In addition, postmenopausal women with osteoporosis on Prolia continued to show gains in bone mineral density (BMD) over 10 years. (amgen.com)
  • Postmenopausal osteoporosis is considered a serious public health concern due to its high prevalence worldwide. (eurekalert.org)
  • Due to its prevalence, osteoporosis is a serious concern to public health," said Julie Beitz, M.D., director of the FDA's Office of Drug Evaluation III. (healthcanal.com)
  • Symptoms related to osteoporosis are not seen unless fractures are present. (clinicaladvisor.com)
  • Whilst there is no 'cure' for osteoporosis, there are ways you can manage your symptoms and take preventative measures to maintain optimum bone health. (healthspan.co.uk)
  • These negative reports on the serious adverse-effects of ERT have led to many postmenopausal women searching for available alternatives for their postmenopausal symptoms. (biomedcentral.com)
  • Lasofoxifene in postmenopausal women with osteoporosis. (nih.gov)
  • In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. (nih.gov)
  • Interest of lasofoxifene in the treatment of osteoporosis. (nih.gov)
  • Lasofoxifene (Fablyn) is used to prevent and treat osteoporosis and raloxifene (Evista) is indicated to do the same in postmenopausal women. (mdmag.com)
  • In postmenopausal women in this osteoporosis prevention trial, those taking lasofoxifene experienced increased sexual activity and orgasm. (mdmag.com)
  • Osteoporosis is a silent skeletal disorder characterized by compromised bone strength that increases the risk of fracture. (medindia.net)
  • Curcumin produces beneficial changes in bone turnover and increases in bone strength using the ovariectomized mature rat model of postmenopausal osteoporosis. (greenmedinfo.com)
  • Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. (clinicaltrials.gov)
  • The USPSTF found good evidence that the risk for osteoporosis and fracture increases with age and other factors, that bone density measurements accurately predict the risk for fractures in the short term, and that treating asymptomatic women with osteoporosis reduces their risk for fracture. (annals.org)
  • New York, NY -- ( SBWIRE ) -- 02/22/2017 -- Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. (sbwire.com)
  • The U.S. Preventive Services Task Force (USPSTF) recommends that women 65 years of age and older be screened routinely for osteoporosis. (annals.org)
  • The US Preventive Services Task Force (USPSTF) recommends screening for osteoporosis with bone mineral density (BMD) testing in all women 65 years or older and in postmenopausal women younger than 65 years but at increased risk of osteoporosis. (cmelist.com)